Compound as DGKζ inhibitor
By developing compounds of general formula (1), the problem of DGKζ inhibition was solved, the killing power of immune cells against tumor cells was enhanced, and the compounds were applied to the treatment of cancer and autoimmune diseases, achieving effective inhibition of DGKζ.
Patent Information
- Application Number
- PCT/CN2024/092900
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-21
- Filing Date
- 2024-05-13
- Publication Date
- 2024-11-21
AI Technical Summary
Existing technologies are insufficient to effectively inhibit the activity of DGKζ protein, resulting in insufficient killing power of the immune response against tumor cells. Furthermore, DGKζ plays an important role in various diseases, and there is a lack of effective means to inhibit it.
A class of compounds of general formula (1) was developed, and compounds with DGKζ inhibitory activity were prepared by synthesizing and optimizing reaction processes 1-4, which can be used to prepare drugs for treating or preventing related diseases.
The compound significantly inhibits DGKζ activity, enhances the killing power of immune cells against tumor cells, and can be used to treat cancers such as hematologic malignancies and solid tumors, and plays a role in autoimmune diseases and inflammatory responses.
Smart Images

Figure CN2024092900_21112024_PF_FP_ABST
Abstract
Description
Compounds that act as DGKζ inhibitors
[0001] This application claims priority to Chinese patent application No. 202310543532.9, filed on May 15, 2023, and Chinese patent application No. 202311769166.5, filed on December 21, 2023. This application incorporates the entirety of the aforementioned Chinese patent application. Technical Field
[0002] The present invention belongs to the field of medicinal chemistry, and more specifically, relates to a class of compounds having DGKζ protein inhibitory effects, a preparation method thereof, and the use of such compounds in preparing drugs for treating or preventing related diseases mediated by DGKζ. Background Art
[0003] DGKα, ζ, and ι belong to the diacylglycerol kinase (DGK) family. DGK represents a family of enzymes that catalyze the phosphorylation of the membrane ester sn-1,2-diacylglycerol (DAG) to form phosphatidic acid (PA). Diacylglycerol (DAG) is a second messenger generated by phospholipase Cγ1 upon TCR engagement, triggering a signaling cascade that plays a crucial role in T cell development and function. DGKs catalyze the phosphorylation of DAG to PA, thereby regulating DAG-mediated signaling. Among them, DGKα and DGKζ are prominently expressed in T cells, with their expression and activity enhanced upon TCR stimulation, and their sustained expression is associated with hyporesponsiveness of tumor-infiltrating T cells.
[0004] Studies have shown that the loss of DGKζ in T cells leads to the production of effector cytokines IL-2 and IFNγ, enhancing the killing effect of T cells on tumor cells. In addition, compared with wild-type CAR T cells, adoptively transferred DGKζ-deficient CAR (chimeric antigen receptor)-T cells showed good synergistic effects in treating mouse mesothelioma and glioblastoma xenograft models in combination with DGKα knockout.
[0005] DGKζ is also associated with natural killer (NK) cells. Upon stimulation by multiple activating receptors, NK cells from mice lacking DGKζ exhibit increased cytokine production and shedding in an ERK-dependent manner. Furthermore, they exhibit improved cytotoxicity against tumor cell lines. In addition to immunomodulation, DGKζ plays other roles in cancer, mediating proliferation, apoptosis, survival, and invasion.
[0006] DGKι can bind to RasGRP3 and reduce Rap1 activation. Inhibiting DGKι activity can significantly reduce Ras signaling pathway activation. In a phorbol ester-induced tumor model, DGKι-deficient mice can significantly inhibit tumor formation compared to wild-type mice.
[0007] Based on current research results, inhibiting DGKζ activity in T cells and tumor cells can produce a stronger immune response to pathogens and tumors. Due to its important role in immunity, DGKζ inhibitors play an important role in malignant solid tumors or hematological tumors (such as acute myeloid leukemia, bladder cancer, breast cancer, colon cancer, lung cancer, pancreatic cancer, melanoma, etc.), autoimmune diseases (such as systemic lupus erythematosus, psoriasis, arthritis, etc.) and inflammatory responses. Inhibiting DGKι activity can reduce the activation of the Ras signaling pathway and inhibit the formation of tumors related to excessive activation of the Ras signaling pathway.
[0008] Summary of the Invention
[0009] The present invention provides a compound represented by general formula (1) or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates:
[0010] In the general formula (1):
[0011] R 2 for
[0012] R 3 is -CH3 or -NH2;
[0013] R x For H or F:
[0014] (1) When R x When H, R 4 is a 6-membered heteroaryl group, wherein the 6-membered heteroaryl group may be optionally substituted by one of the following groups: phenyl, wherein the phenyl group may be optionally substituted by one, two or three of the following groups: -H, halogen, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, -(C1-C3) alkylene-phenyl, -(C1-C3) alkylene-(5-6 membered) heteroaryl, -(C1-C3) alkylene-(C3-C7) heterocycloalkyl, -(C1-C3) alkylene-(OR 9 ), (C3-C7) cycloalkyl, -OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-(N(R 10 )(R 11 ))、-C(=O)-N(R 12 )(R 13 ), -S(=O) n -R 14 、-C(=O)R 14 or -C(=O)-OR 17 ;and
[0015] R 1 is phenyl or (5-6 membered) heteroaryl, wherein said phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -OH, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, -(C1-C3) alkylene-phenyl, (C1-C6) alkoxy, -(C1-C3) alkyleneoxy-phenyl, (C1-C6) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl group in said -(C1-C3)alkylene-phenyl and -(C1-C3)alkyleneoxy-phenyl may each independently be optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3;
[0016] (2) When R x When H, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -N=S(R a )(R b )(=O)、-P(O)(R a )(R b ), (C2-C6)alkenyl, (C5-C6)cycloalkenyl, (C2-C6)alkynyl, (C2-C6)haloalkenyl, (C5-C6)halocycloalkenyl, (C2-C6)haloalkynyl, (4-7 membered)heterocycloalkyl attached via a carbon atom in the heterocycle, -O-(C2-C6)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C6)alkynyl, -O-(C1-C6)alkylene-(C3-C7)cycloalkyl, -S-(C1-C6)alkylene-(C3-C7)cycloalkyl, -O-(C1-C6)alkylene-(3-C7 membered)heterocycloalkyl, -S-(C1-C6)alkylene-(3-7)heterocycloalkyl, or -O-(C1-C6)alkylene-N(R 10 )(R 11), wherein the (4-7 membered) heterocycloalkyl, -O-(C1-C4) alkylene-(3-7 membered) heterocycloalkyl and the (3-7 membered) heterocycloalkyl in -S-(C1-C4) alkylene-(3-7 membered) heterocycloalkyl are each independently optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; and wherein the (C2-C6) alkenyl, (C5-C6)cycloalkenyl, (C2-C6)alkynyl, (C2-C6)haloalkenyl, (C5-C6)halocycloalkenyl or (C2-C6)haloalkynyl may each independently be optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -OH, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C3-C6)cycloalkyl, (3-7 membered)heterocycloalkyl, optionally substituted (5-7 membered)heteroaryl or optionally substituted phenyl; and R 1 is phenyl or (5-6 membered) heteroaryl, wherein said phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -OH, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, -(C1-C3) alkylene-phenyl, (C1-C6) alkoxy, -(C1-C3) alkyleneoxy-phenyl, (C1-C6) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl group in said -(C1-C3)alkylene-phenyl and -(C1-C3)alkyleneoxy-phenyl may each independently be optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3;
[0017] (3) When R x When H, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, -(C1-C3) alkylene-phenyl, -(C1-C3) alkylene-(5-6 membered) heteroaryl, -(C1-C3) alkyl-(3-7 membered) heterocycloalkyl, -(C1-C6) alkylene-(OR 9 ), (C3-C7) cycloalkyl, -OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-(N(R10 )(R 11 ))、-C(=O)-N(R 12 )(R 13 ), -S(=O) n -R 14 、-C(=O)R 14 、-C(=O)-OR 17 , (5-6 membered) heteroaryl substituted by 1 or 2 halogen or -CH3 or phenyl substituted by 1 or 2 halogen or -CH3; and
[0018] R 1 is phenyl or (5-6 membered)heteroaryl, wherein the phenyl or (5-6 membered)heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: (C2-C6)alkenyl, (C5-C6)cycloalkenyl, (C2-C6)alkynyl, (C2-C6)haloalkenyl, (C5-C6)halocycloalkenyl or (C2-C6)haloalkynyl;
[0019] (4) When R x When F, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl, (C5-C6) halocycloalkenyl, (C2-C6) haloalkynyl, (4-7 membered) heterocyclic Alkyl, -O-(C2-C6)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C6)alkynyl, -O-(C2-C6)haloalkenyl, -O-(C5-C6)halocycloalkenyl, -O-(C2-C6)haloalkynyl, -(C1-C3)alkylene-phenyl, -(C1-C3)alkylene-(5-6 membered)heteroaryl, -(C1-C3)alkylene-(C3-C7)cycloalkyl, -(C1-C6)alkylene-(OR 9 ), (C3-C7) cycloalkyl, -OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-(N(R 10 )(R 11 ))、-C(=O)-N(R 12 )(R 13 ), -S(=O) n -R 14 、-C(=O)R 14 、-C(=O)-OR 17, (5-6 membered) heteroaryl substituted by 1 or 2 halogen or -CH3, or phenyl substituted by 1 or 2 halogen or -CH3, wherein the (4-7 membered) heterocycloalkyl is optionally substituted by 1 or 2 of -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2, or -CF3; and
[0020] R 1 is phenyl or (5-6 membered) heteroaryl, wherein said phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -OH, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, -(C1-C3) alkylene-phenyl, (C1-C6) alkoxy, -(C1-C3) alkoxy-phenyl, (C1-C6) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl group in said -(C1-C3)alkylene-phenyl and -(C1-C3)alkyleneoxy-phenyl may each independently be optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3;
[0021] R a and R b Each is independently (C1-C4)alkyl or (C3-C4)cycloalkyl;
[0022] R 5 and R 6 each independently -H, (C1-C4)alkyl, -C(=O)-(C1-C4)alkyl, (C3-C4)cycloalkyl, or -(C1-C3)alkylene-phenyl;
[0023] or R 5 and R 6 Together with the nitrogen atom to which it is attached, a (4-7 membered) heterocycloalkyl group may be formed, wherein the (4-7 membered) heterocycloalkyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -OH, (C1-C4)alkyl, -C(=O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or (C1-C4)alkoxy;
[0024] R 7 is H, -CH3 or -CH2CH3;
[0025] R 8is -C(=O)NH2 or -S(=O)2NH2;
[0026] R 9 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, (C1-C6) alkyl, -(C1-C3) alkylene-(5-6 membered) heteroaryl, -(C1-C3) alkylene-phenyl, (C1-C6) haloalkyl, hydroxy-substituted (C2-C4) alkyl, -(C2-C3) alkylene-(C1-C3) alkoxy, -(C2-C3) alkylene-OC(=O)-(C1-C3) alkyl, -C(R 18 )(R 19 )-C(=O)-OR 17 、-C(R 18 )(R 19 )-C(=O)-N(R 20 )(R 21 )、-C(=O)-N(R 20 )(R 21 ), phenyl, (5-6 membered) heteroaryl or (5-6 membered) heterocycloalkyl, wherein the phenyl in -(C1-C3)alkylene-phenyl, phenyl, (5-6 membered) heteroaryl, (5-6 membered) heteroaryl and (5-6 membered) heterocycloalkyl in -(C1-C3)alkylene-(5-6 membered) heteroaryl can each independently be optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3;
[0027] R 10 and R 11 Each is independently -H, (C1-C4) alkyl, (C1-C4) haloalkyl, hydroxy-substituted (C2-C4) alkyl, -(C2-C3) alkylene-(C1-C3) alkoxy, -(C2-C3) alkylene-(N(R 22 )(R 23)), -(C1-C6)alkylene-(C3-C7)cycloalkyl, -C(=O)-(C1-C4)alkyl, (C3-C7)cycloalkyl, -C(=O)-(C3-C7)cycloalkyl, -(C1-C3)alkylene-phenyl, -C(=O)-(C1-C3)alkylene-phenyl, -C(=O)-O-(C1-C3)alkylene-phenyl, phenyl or (5-6 membered)heteroaryl, wherein the (C3-C7)cycloalkyl, -(C1-C6)alkylene-(C3-C7)cycloalkyl and -C (C3-C7)cycloalkyl, -(C1-C3)alkylene-phenyl, -C(=O)-(C1-C3)alkylene-phenyl, -C(=O)-O-(C1-C3)alkylene-phenyl, phenyl or (5-6 membered)heteroaryl in (=O)-(C3-C7)cycloalkyl may each independently be optionally substituted with 1 or 2 of the following groups: -H, -F, -CN, -CH3, -CH2CH3, -CF3, -OCF3, -CH2CF3, -OCH3, -OCH2CH3 or -N(CH3)2;
[0028] or R 10 and R 11 Together with the nitrogen atom to which it is attached, it can form a (4-11 membered) heterocycloalkyl, wherein said (4-11 membered) heterocycloalkyl can be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -OH, (C1-C4) alkyl, (C1-C4) haloalkyl, -C(=O)-(C1-C4) alkyl, (C3-C7) cycloalkyl, (C1-C4) alkoxy, -N(R 22 )(R 23 ) or (4-7 membered) heterocycloalkyl;
[0029] R 12 and R 13 Each is independently -H, (C1-C4) alkyl, (C1-C4) haloalkyl, hydroxy-substituted (C1-C4) alkyl, -(C2-C3) alkylene-(C1-C4) alkoxy, -(C2-C3) alkylene-(C1-C4) haloalkoxy, -(C2-C3) alkylene-phenoxy, (C3-C7) cycloalkyl, (C4-C7) heterocycloalkyl or -(C1-C3) alkylene-phenyl, wherein the phenyl, (C3-C7) cycloalkyl and (C4-C7) heterocycloalkyl in the -(C2-C3) alkylene-phenoxy and -(C1-C3) alkylene-phenyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, -N(CH3)2, (C1-C4)alkyl, (C1-C4)haloalkyl, -C(=O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or (C1-C4)alkoxy;
[0030] or R 12 and R 13 Together with the nitrogen atom to which it is attached, a (4-7 membered) heterocycloalkyl group may be formed, wherein the (4-7 membered) heterocycloalkyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, (C1-C4)alkyl, -C(=O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or (C1-C4)alkoxy;
[0031] R 14 is (C1-C4)alkyl, (C1-C4)alkoxy or phenyl, wherein the phenyl group may be independently optionally substituted with 1, 2 or 3 of the following groups: -H, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3;
[0032] R 17 is (C1-C4)alkyl;
[0033] R 18 and R 19 Each is independently -H or (C1-C4)alkyl;
[0034] R 20 is H, (C1-C6) alkyl, (C3-C4) alkenyl, (C2-C4) alkynyl or (C1-C3) alkoxy, wherein the (C1-C6) alkyl may be substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, (C1-C4) alkoxy, -N(R 22 )(R 23 ), (C3-C11)cycloalkyl, (4-11 membered)heterocycloalkyl, phenyl or (5-10 membered)heteroaryl, wherein the phenyl or (5-10 membered)heteroaryl may be substituted by 1, 2 or 3 of the following groups: -H, -F, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3;
[0035] or R 20 is (C3-C11)cycloalkyl, (4-11 membered)heterocycloalkyl, wherein said (C3-C11)cycloalkyl and (4-11 membered)heterocycloalkyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, (C1-C4)alkyl, -C(=O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or (C1-C4)alkoxy;
[0036] or R 20is phenyl, naphthyl or (5-10 membered) heteroaryl, wherein the phenyl, naphthyl and (5-10 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, (C1-C4) alkyl, (C1-C4) haloalkyl, (C1-C4) alkoxy, (C1-C4) haloalkoxy, -N(R 22 )(R 23 ) or -C(=O)(R 24 )(R 25 );
[0037] R 21 is H or (C1-C4) alkyl;
[0038] or R 20 and R 21 Together with the nitrogen atom to which it is attached, a (4-7 membered) heterocycloalkyl group may be formed, wherein the (4-7 membered) heterocycloalkyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -OH, (C1-C4) alkyl, (C1-C4) haloalkyl, -(C1-C3) alkylene-phenyl, -C(=O)-(C1-C4) alkyl, (C3-C4) cycloalkyl, (C1-C4) alkoxy, (C1-C3) haloalkoxy, -N(R 22 )(R 23 ) or -C(=O)(R 24 )(R 25 );
[0039] R 22 and R 23 Each is independently -H, (C1-C2)alkyl or -C(=O)-(C1-C2)alkyl;
[0040] R 24 and R 25 are each independently -H or (C1-C4)alkyl; and
[0041] n is an integer of 0, 1 or 2.
[0042] In another preferred embodiment, wherein in the general formula (1), R 2 for
[0043] In another preferred embodiment, wherein in the general formula (1), when R x When F, R 4is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -I, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, (C2-C4) haloalkyl -C1-C2)alkylene-phenyl, -(C1-C2)alkylene-(5-6 membered)heteroaryl, -(C1-C2)alkylene-(C3-C7)cycloalkyl, -(C1-C4)alkylene-(OR 9 )、(C3-C7)cycloalkyl, -OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-N(R 10 )(R 11 )、-C(=O)-N(R 12 )(R 13 ),-SR 14 、-S(=O)-R 14 、-S(=O)2-R 14 、-C(=O)R 14 、-C(=O)-OR 17 , (5-6 membered)heteroaryl substituted with 1 or 2 -F, -Cl, -Br or -CH3, or phenyl substituted with 1 or 2 -F, -Cl, -Br or -CH3, wherein the (4-7 membered)heterocycloalkyl is optionally substituted with 1 or 2 of -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; and
[0044] R 1 is phenyl or (5-6 membered) heteroaryl, wherein said phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -OH, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, -(C1-C2) alkylene-phenyl, (C1-C4) alkoxy, -(C1-C2) alkyleneoxy-phenyl, (C1-C4) haloalkoxy or -N(R 5)(R 6 ), wherein the phenyl group in the -(C1-C2)alkylene-phenyl group and the -(C1-C2)alkyleneoxy-phenyl group may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -Br, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
[0045] In another preferred embodiment, wherein in the general formula (1), R 4 is phenyl or (5-6 membered) heteroaryl containing 1, 2 or 3 independently selected from N, O or S, wherein said phenyl and (5-6 membered) heteroaryl are each independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3; and
[0046] R 1 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3.
[0047] In another preferred embodiment, wherein in the general formula (1), when R x When F, R 4 for:
[0048] R 1 for
[0049] In another preferred embodiment, wherein in the general formula (1), when R x When H, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -N=S(CH3)2(=O), -P(O)(CH3)2, (C2-C4)alkenyl, (C5-C6)cycloalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkenyl, (C5-C6)halocycloalkenyl, (C2-C4)haloalkynyl, (4-7 membered)heterocycloalkyl attached via a carbon atom in the heterocycle, -O-(C2-C4)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C4)alkynyl, - O-(C1-C4)alkylene-(C3-C7)cycloalkyl, -S-(C1-C4)alkylene-(C3-C7)cycloalkyl, -O-(C1-C4)alkylene-(3-7 membered)heterocycloalkyl, -S-(C1-C4)alkylene-(3-7 membered)heterocycloalkyl or -O-(C1-C4)alkylene-N(R10 )(R 11 ), wherein the (4-7 membered) heterocycloalkyl, -O-(C1-C4) alkylene-(3-7 membered) heterocycloalkyl and the (3-7 membered) heterocycloalkyl in -S-(C1-C4) alkylene-(3-7 membered) heterocycloalkyl may each be independently optionally substituted with 1 or 2 of the following groups: -H, -F, -Cl, -Br, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N( CH3)2 or -CF3; and wherein the (C2-C4)alkenyl, (C5-C6)cycloalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkenyl, (C5-C6)halocycloalkenyl or (C2-C4)haloalkynyl may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -CN, -OH, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -CF3, optionally substituted (5-6 membered) heteroaryl or optionally substituted phenyl; and
[0050] R 1 is phenyl or (5-6 membered) heteroaryl, wherein said phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -OH, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, -(C1-C2) alkylene-phenyl, (C1-C4) alkoxy, -(C1-C2) alkyleneoxy-phenyl, (C1-C4) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl group in the -(C1-C2)alkylene-phenyl group and the -(C1-C2)alkyleneoxy-phenyl group may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -Br, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
[0051] In another preferred embodiment, wherein in the general formula (1), R 4is phenyl or a (5-6 membered) heteroaryl group containing 1, 2 or 3 independently selected from N, O or S, wherein the phenyl group and the (5-6 membered) heteroaryl group are each independently optionally substituted by 1, 2 or 3 of the following groups: -N=S(CH3)2(=O), -P(O)(CH3)2, (C2-C3)alkenyl, (C2-C3)haloalkenyl, (C5-C6)cycloalkenyl, (C5-C6)halocycloalkenyl, (C2-C3)alkynyl, (C2-C3)haloalkynyl, a ... independently selected from N, S or O (4-7 membered) heterocycloalkyl, -O-(C2-C4) alkenyl, -O-(C5-C6) cycloalkenyl, -O-(C2-C4) alkynyl, -O-(C1-C2) alkylene-(C3-C6) cycloalkyl, -S-(C1-C2) alkylene-(C3-C6) cycloalkyl, -O-(C1-C2) alkylene-(3-6 membered) heterocycloalkyl, -S-(C1-C2) alkylene-(3-6 membered) heterocycloalkyl or -O-(C1-C2) alkylene-N(R 10 )(R 11 ), wherein the heterocycloalkyl in said (4-7 membered)heterocycloalkyl, -O-(C1-C2)alkylene-(3-6 membered)heterocycloalkyl and -S-(C1-C2)alkylene-(3-6 membered)heterocycloalkyl can each independently be optionally substituted with 1 or 2 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3; and wherein said (C2-C3)alkenyl, (C5-C6)cycloalkenyl, (C2-C3)alkynyl, (C2-C3)haloalkenyl, (C5-C6)halocycloalkenyl or (C2-C3)haloalkynyl can each independently be optionally substituted with 1 or 2 of the following groups: -H, -F, -Cl, -CN, -OH, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -CF3,
[0052] R 1 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3.
[0053] In another preferred embodiment, wherein in the general formula (1), R 4 is phenyl, pyridyl or oxadiazolyl, wherein the phenyl, pyridyl or oxadiazolyl are each independently optionally substituted by 1, 2 or 3 of the following groups:
[0054] R 1is phenyl, wherein said phenyl is independently optionally substituted with 1, 2 or 3 of the following groups: H, F and Cl.
[0055] In another preferred embodiment, wherein in the general formula (1), R 4 for:
[0056] R 1 for
[0057] In another preferred embodiment, wherein in the general formula (1), R 4 for:
[0058] R 1 for
[0059] In another preferred embodiment, wherein in the general formula (1), when R x When H, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -I, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, (C2-C4) haloalkenyl, (C5-C6) halocycloalkenyl, (C2-C4) halo Alkynyl, -O-(C2-C4)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C4)alkynyl, -O-(C2-C4)haloalkenyl, -O-(C5-C6)halocycloalkenyl, -O-(C2-C4)haloalkynyl, -(C1-C2)alkylene-phenyl, -(C1-C2)alkylene-(5-6 membered)heteroaryl, -(C1-C2)alkylene-(C3-C7)cycloalkyl, -(C1-C4)alkylene-(OR 9 ), (C3-C7) cycloalkyl, -OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-N(R 10 )(R 11 )、-C(=O)-N(R 12 )(R 13 ),-SR 14 、-S(=O)-R 14、-S(=O)2-R 14 、-C(=O)R 14 、-C(=O)- OR 17 , (5-6 membered) heteroaryl substituted by 1 or 2 -F, -Cl, -Br or -CH3 or phenyl substituted by 1 or 2 -F, -Cl, -Br or -CH3; and
[0060] R 1 is phenyl or (5-6 membered)heteroaryl, wherein the phenyl or (5-6 membered)heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: (C2-C4)alkenyl, (C5-C6)cycloalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkenyl, (C5-C6)halocycloalkenyl or (C2-C4)haloalkynyl.
[0061] In another preferred embodiment, wherein in the general formula (1), R 4 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3; and
[0062] R 1 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: (C2-C3)alkenyl, (C2-C3)alkynyl, (C2-C3)haloalkenyl, (C5-C6)cycloalkenyl, (C5-C6)halocycloalkenyl.
[0063] In another preferred embodiment, wherein in the general formula (1), R 4 is phenyl, wherein said phenyl is independently optionally substituted with 1, 2 or 3 of the following groups: H, F and Cl; and
[0064] R 1 is phenyl, wherein said phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups:
[0065] In another preferred embodiment, wherein in the general formula (1), R 4 for:
[0066] R 1 for
[0067] In another preferred embodiment, wherein in the general formula (1), when R x When H, R 4is a 6-membered heteroaryl group, wherein the 6-membered heteroaryl group may be optionally substituted by one of the following groups: phenyl, wherein the phenyl group may be optionally substituted by one, two or three of the following groups: -H, -F, -Cl, -Br, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, -(C1-C2) alkylene-phenyl, -(C1-C2) alkylene-(5-6 membered) heteroaryl, -(C1-C2) alkylene-(C3-C7) heterocycloalkyl, -(C1-C2) alkylene-(OR 9 ), (C3-C7) cycloalkyl, -OR 9 、-N(R 10 )(R 11 )、-(C1-C2)alkylene-N(R 10 )(R 11 )、-C(=O)-N(R 12 )(R 13 ),-SR 14 、-S(=O)-R 14 、-S(=O)2-R 14 、-C(=O)R 14 or -C(=O)-OR 17 ;and
[0068] R 1 is phenyl or (5-6 membered) heteroaryl, wherein said phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -OH, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, -(C1-C2) alkylene-phenyl, (C1-C4) alkoxy, -(C1-C2) alkyleneoxy-phenyl, (C1-C4) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl group in the -(C1-C2)alkylene-phenyl group and the -(C1-C2)alkyleneoxy-phenyl group may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -Br, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
[0069] In another preferred embodiment, wherein in the general formula (1), R 4is a 6-membered heteroaryl containing 1 or 2 N, wherein the 6-membered heteroaryl is substituted by 1 of the following groups: phenyl, wherein the phenyl is independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -CN, -NO2, -CH3, -CH2CH3, -CHF2, -CF3, -OR 9 、-N(R 10 )(R 11 )、-C(=O)-N(R 12 )(R 13 );and
[0070] R 1 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3.
[0071] In another preferred embodiment, wherein in the general formula (1), R 4 is pyridinyl, pyrimidinyl or pyrazinyl, wherein said pyridinyl, pyrimidinyl or pyrazinyl is substituted with 1 of the following groups: phenyl, wherein said phenyl is independently optionally substituted with 1, 2 or 3 of the following groups: -H, -F, -Cl, -CN, -NO2, -CH3, -CHF2, -CF3, -OCH3, -OCHF2, -OCF3, -N(CH3)2, -C(=O)-NH2, -C(=O)-NH(CH3), -C(=O)-N(CH3)2; and
[0072] R 1 is phenyl, wherein said phenyl is independently optionally substituted with 1, 2 or 3 of the following groups: H, F and Cl.
[0073] In another preferred embodiment, wherein in the general formula (1), R 4 for:
[0074] R 1 for
[0075] In another preferred embodiment, wherein in the general formula (1), R 4 for
[0076] R 1 for
[0077] In another preferred embodiment, wherein in the general formula (1), R a and R b Each is independently -CH3 or -CH2CH3.
[0078] In another preferred embodiment, wherein in the general formula (1), R 5 and R 6 each independently -H, (C1-C3)alkyl, -C(=O)-(C1-C3)alkyl, (C3-C4)cycloalkyl, or -(C1-C2)alkylene-phenyl;
[0079] or R 5 and R 6 Together with the nitrogen atom to which it is attached, a (4-6 membered) heterocycloalkyl group may be formed, wherein the (4-6 membered) heterocycloalkyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -OH, -CH3, -CH2CH3, -C(=O)-CH3, -OCH3 or -OCH2CH3.
[0080] In another preferred embodiment, wherein in the general formula (1), R 5 and R 6 Each is independently -H, -CH3, -CH2CH3, -C(=O)-CH3,
[0081] In another preferred embodiment, wherein in the general formula (1), R 9 is H, (C1-C4) alkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, (C1-C4) alkyl, -(C1-C2) alkylene-(5-6 membered) heteroaryl, -(C1-C2) alkylene-phenyl, (C1-C4) haloalkyl, hydroxy-substituted (C2-C3) alkyl, -(C2-C3) alkylene-(C1-C2) alkoxy, -(C2-C3) alkylene-OC(=O)-(C1-C2) alkyl, -C(R 18 )(R 19 )-C(=O)-OR 17 、-C(R 18 )(R 19 )-C(=O)-N(R 20 )(R 21 )、-C(=O)-N(R 20 )(R 21), phenyl, (5-6 membered) heteroaryl or (5-6 membered) heterocycloalkyl, wherein the phenyl in -(C1-C2)alkylene-phenyl, phenyl, (5-6 membered) heteroaryl, (5-6 membered) heteroaryl and (5-6 membered) heterocycloalkyl can each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
[0082] In another preferred embodiment, wherein in the general formula (1), R 9 For H, -CHF2, -CF3, -CH2CF3,
[0083] In another preferred embodiment, wherein in the general formula (1), R 10 and R 11 Each is independently -H, (C1-C2) alkyl, (C1-C2) haloalkyl, hydroxy-substituted (C2-C3) alkyl, -(C2-C3) alkylene-(C1-C2) alkoxy, -(C2-C3) alkylene-N(R 22 )(R 23 ), -(C1-C2)alkylene-(C3-C7)cycloalkyl, -C(=O)-(C1-C2)alkyl, (C3-C7)cycloalkyl, -C(=O)-(C3-C7)cycloalkyl, -(C1-C2)alkylene-phenyl, -C(=O)-(C1-C2)alkylene-phenyl, -C(=O)-O-(C1-C2)alkylene-phenyl, phenyl or (5-6 membered)heteroaryl, wherein the (C3-C7)cycloalkyl, -(C1-C6)alkyl-(C3-C7)cycloalkyl and -C(=O)-(C3-C7)cycloalkyl The (C3-C7)cycloalkyl group in -(C1-C2)alkylene-phenyl and -C(=O)-(C1-C2)alkylene-phenyl and the phenyl, phenyl or (5-6 membered)heteroaryl group in -C(=O)-O-(C1-C2)alkylene-phenyl may each independently be optionally substituted with 1 or 2 of the following groups: -H, -F, -CN, -CH3, -CH2CH3, -CF3, -OCF3, -CH2CF3, -OCH3, -OCH2CH3 or -N(CH3);
[0084] or R 10 and R 11 Together with the nitrogen atom to which it is attached, a (4-7 membered) heterocycloalkyl group may be formed, wherein the (4-7 membered) heterocycloalkyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -CN, -OH, -CH3, -CH2CH3, -CF3, CH3- C(=O)-, -OCH3, -OCH2CH3, -NH2, -N(CH3)2 or (4-7 membered)heterocycloalkyl.
[0085] In another preferred embodiment, wherein in the general formula (1), R 10 and R 11 Each is independently -H, -CH3, -CH2CH3, -C(=O)-CH3,
[0086] In another preferred embodiment, wherein in the general formula (1), R 12 and R 13 Each is independently -H, (C1-C3) alkyl, (C1-C3) haloalkyl, hydroxy-substituted (C1-C3) alkylene-(C1-C3) alkoxy, -(C2-C3) alkylene-(C1-C3) haloalkoxy, -(C2-C3) alkylene-phenoxy, (C3-C7) cycloalkyl, (C4-C7) heterocycloalkyl or -(C1-C2) alkylene-phenyl, wherein the phenyl, (C3-C7) cycloalkyl and (C4-C7) heterocycloalkyl in the -(C2-C3) alkylene-phenoxy and -(C1-C2) alkylene-phenyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, -N(CH3)2, -CH3, -CH2CH3, -CF3, -C(=O)-CH3, -OCH3 or -OCH2CH3;
[0087] or R 12 and R 13 Together with the nitrogen atom to which it is attached, a (4-7 membered) heterocycloalkyl group may be formed, wherein the (4-7 membered) heterocycloalkyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, -CH3, -CH2CH3, CH3-C(=O)-, -OCH3 or -OCH2CH3.
[0088] In another preferred embodiment, wherein in the general formula (1), R 12 and R 13 are independently -H, -CH3, -CH2CH3,
[0089] In another preferred embodiment, wherein in the general formula (1), R14 is (C1-C2)alkyl, (C1-C2)alkoxy or phenyl, wherein the phenyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
[0090] In another preferred embodiment, wherein in the general formula (1), R 14 It is -CH3, -CH2CH3, -OCH3 or -OCH2CH3.
[0091] In another preferred embodiment, wherein in the general formula (1), R 17 It is -CH3 or -CH2CH3.
[0092] In another preferred embodiment, wherein in the general formula (1), R 18 and R 19 Each is independently -H, -CH3 or -CH2CH3.
[0093] In another preferred embodiment, wherein in the general formula (1), R 20 is H, (C1-C3)alkyl, (C3-C4)alkenyl, (C2-C4)alkynyl or (C1-C3)alkoxy, wherein the (C1-C3)alkyl may be substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -CN, -OCH3, -OCH2CH3, -NH2, -N(CH3)2, (C3-C7)cycloalkyl, (4-7 membered)heterocycloalkyl, phenyl or (5-10 membered)heteroaryl, wherein the phenyl or (5-10 membered)heteroaryl may be substituted by 1, 2 or 3 of the following groups: -H, -F, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3;
[0094] or R 20 is (C3-C7) cycloalkyl, (4-7 membered) heterocycloalkyl, wherein the (C3-C7) cycloalkyl and (4-7 membered) heterocycloalkyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, -CH3, -CH2CH3, CH3-C(=O)-, -OCH3 or -OCH2CH3;
[0095] or R 20is phenyl, naphthyl or (5-10 membered)heteroaryl, wherein the phenyl, naphthyl and (5-10 membered)heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -CF3, -N(CH3)2 or -C(=O)(CH3)2.
[0096] In another preferred embodiment, wherein in the general formula (1), R 21 is H, -CH3 or -CH2CH3;
[0097] or R 20 and R 21 Together with the nitrogen atom to which it is attached, a (4-7 membered) heterocycloalkyl group may be formed, wherein the (4-7 membered) heterocycloalkyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, -(C1-C2)alkylene-phenyl, -C(=O)-CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -C(=O)(CH3)2.
[0098] In another preferred embodiment, wherein in the general formula (1), R 22 and R 23 Each is independently -H, -CH3, -CH2CH3 or -C(=O)-CH3.
[0099] In another preferred embodiment, wherein in the general formula (1), R 24 and R 25 Each is independently -H, -CH3 or -CH2CH3.
[0100] In another specific embodiment of the present invention, the compound of formula (1) has one of the following structures:
[0101] In another specific embodiment of the present invention, the compound of formula (1) has one of the following structures:
[0102] In another specific embodiment of the present invention, the compound of formula (1) has one of the following structures:
[0103] Another object of the present invention is to provide a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent and / or excipient, and a compound of the general formula (1) of the present invention, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as active ingredients.
[0104] Another object of the present invention is to provide the use of the compound represented by general formula (1) of the present invention, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, or the pharmaceutical composition thereof, for preparing a drug for treating, regulating or preventing a disease associated with the DGKζ protein. The disease is preferably cancer, and the cancer is a blood cancer or a solid tumor.
[0105] Another object of the present invention is to provide a method for treating, regulating or preventing diseases related to DGKζ protein, comprising administering to a subject a therapeutically effective amount of a compound represented by general formula (1) of the present invention, or its isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates, or the above-mentioned pharmaceutical composition.
[0106] By synthesizing and carefully studying a variety of new compounds with DGKζ inhibitory effects, the inventors found that among the compounds of formula (1), the compounds unexpectedly have strong DGKζ inhibitory activity.
[0107] It is to be understood that both the foregoing general description and the following detailed description of the present invention are exemplary and explanatory and are intended to provide further explanation of the invention as claimed.
[0108] Synthesis of compounds
[0109] The following specifically describes the preparation methods of the compound of general formula (1) of the present invention, but these specific methods do not constitute any limitation to the present invention.
[0110] The compounds of formula (1) described above can be synthesized using standard synthetic techniques or known techniques in combination with the methods described herein. In addition, the solvents, temperatures and other reaction conditions mentioned herein may vary. The starting materials used in the synthesis of the compounds can be synthesized or obtained from commercial sources. The compounds described herein and other related compounds having different substituents can be synthesized using known techniques and starting materials, including those found in March, ADVANCED ORGANIC CHEMISTRY 4 th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4 thEd., Vols.A and B (Plenum 2000, 2001), Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3 rd Ed., (Wiley 1999). The general methods for the preparation of compounds can be modified by using appropriate reagents and conditions to introduce various groups into the formulae provided herein.
[0111] On the one hand, the compounds described herein are prepared according to methods known in the art. However, the conditions of the methods, such as reactants, solvents, bases, the amounts of the compounds used, reaction temperatures, reaction times, etc., are not limited to the following explanations. The compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such combinations can be easily performed by those skilled in the art. On the one hand, the present invention also provides a method for preparing the compound of the general formula (1), wherein the compound of the general formula (1) can be prepared using the following general reaction schemes 1-4:
[0112] General reaction scheme 1
[0113] An embodiment of the compound of formula (1) can be prepared according to the general reaction scheme 1, wherein R 1 、R 4 、R 7 and R x As defined above, N represents nitrogen, O represents oxygen, S represents sulfur, Cl represents chlorine, and Br represents bromine. As shown in General Reaction Scheme 1, compound 1-1 undergoes a substitution reaction with NH2CN to produce compound 1-2, compound 1-2 and compound 1-3 undergo a condensation reaction to produce compound 1-4, compound 1-4 reacts with (Boc)2O to produce compound 1-5, and compound 1-5 undergoes a substitution reaction with compound 1-6 to produce target compound 1-7. In some cases, compound 1-7 can be subjected to chiral resolution to yield optical isomers 1-7-A and 1-7-B.
[0114] General reaction scheme 2
[0115] An embodiment of the compound of formula (1) can be prepared according to general reaction scheme 2, wherein R 1 、R 7 and R xAs defined above, ring A is a substituted benzene ring or a substituted heteroaryl ring, ring B is a substituted cycloalkenyl group or a substituted heterocycloalkenyl group, ring C is a substituted cycloalkyl group or a substituted heterocycloalkyl group, N represents nitrogen, O represents oxygen, S represents sulfur, Cl represents chlorine, Br represents bromine, and X represents Br, Cl, or I. As shown in General Reaction Scheme 2, compound 2-1 undergoes a substitution reaction with NH2CN to produce compound 2-2, compound 2-2 and compound 2-3 undergo a condensation reaction to produce compound 2-4, compound 2-4 reacts with (Boc)2O to produce compound 2-5, compound 2-5 and compound 2-6 undergo a coupling reaction to produce compound 2-7, compound 2-7 and compound 2-8 undergo a substitution reaction to produce target compound 2-9, and compound 2-9 undergoes a hydrogenation reaction to produce compound 2-10. In some cases, compound 2-10 is subjected to chiral resolution to obtain optical isomers 2-10-A and 2-10-B.
[0116] General reaction scheme 3
[0117] Embodiments of compounds of formula (1) can be prepared according to general reaction scheme 3, wherein R 1 、R 7 and R x As defined above, ring A is a substituted benzene ring or a substituted heteroaryl group, ring D is a substituted benzene ring or a substituted heteroaryl group, N represents nitrogen, O represents oxygen, S represents sulfur, Cl represents chlorine, Br represents bromine, and X represents Br, Cl, or I. As shown in General Reaction Scheme 3, compound 3-1 undergoes a substitution reaction with NH2CN to produce compound 3-2, compound 3-2 and compound 3-3 undergo a condensation reaction to produce compound 3-4, compound 3-4 reacts with (Boc)2O to produce compound 3-5, compound 3-5 and compound 3-6 undergo a coupling reaction to produce compound 3-7, and compound 3-7 and compound 3-8 undergo a substitution reaction to produce target compound 3-9. In some cases, compound 3-9 is subjected to chiral resolution to obtain optical isomers 3-9-A and 3-9-B.
[0118] General reaction scheme 4
[0119] The embodiment of the compound of formula (1) can be prepared according to the general reaction scheme 4, wherein R 1 、R 7 and R x As defined above, ring A is a substituted benzene ring or a substituted heteroaryl ring, R 0is a substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, substituted cycloalkynyl, substituted haloalkyl, substituted haloalkenyl, or substituted haloalkynyl, N represents nitrogen, O represents oxygen, S represents sulfur, Cl represents chlorine, Br represents bromine, and X represents Br, Cl, or I. As shown in General Reaction Scheme 4, compound 4-1 undergoes a substitution reaction with NH2CN to produce compound 4-2, compound 4-2 and compound 4-3 undergo a condensation reaction to produce compound 4-4, compound 4-4 reacts with (Boc)2O to produce compound 4-5, compound 4-5 and compound 4-6 undergo a coupling reaction to produce compound 4-7, and compound 4-7 and compound 4-8 undergo a substitution reaction to produce target compound 4-9. In some cases, compound 4-9 is subjected to chiral resolution to obtain optical isomers 4-9-A and 4-9-B.
[0120] Further forms of compounds
[0121] "Pharmaceutically acceptable" as used herein refers to a substance, such as a carrier or diluent, that does not abrogate the biological activity or properties of the compound and is relatively non-toxic, i.e., a substance that does not cause undesirable biological effects or interact in a deleterious manner with any of its components when administered to a subject.
[0122] The term "pharmaceutically acceptable salt" refers to a form of a compound that does not cause significant irritation to the organism to which it is administered and does not abrogate the biological activity and properties of the compound. In certain specific aspects, pharmaceutically acceptable salts are obtained by reacting a compound of the formula with an acid or base, wherein the acid or base includes, but is not limited to, those found in Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use 1. st Acids and Bases in Ed., (Wiley, 2002).
[0123] It should be understood that references to pharmaceutically acceptable salts include solvent-added forms or crystallized forms, particularly solvates or polymorphs. Solvates contain stoichiometric or non-stoichiometric amounts of solvent and are selectively formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is ethanol. Solvates of compounds of formula (1) are conveniently prepared or formed according to the methods described herein. For example, hydrates of compounds of formula (1) are conveniently prepared by recrystallization from a mixed solvent of water / organic solvent, using organic solvents including, but not limited to, tetrahydrofuran, acetone, ethanol or methanol. In addition, the compounds mentioned herein can exist in unsolvated and solvated forms. In general, for the purposes of the compounds and methods provided herein, the solvated forms are considered to be equivalent to the unsolvated forms.
[0124] In other embodiments, the compound of formula (1) is prepared in different forms, including but not limited to, amorphous, crushed and nano-particle forms. In addition, the compound of formula (1) includes crystalline forms and can also be polymorphic. Polymorphs include different lattice arrangements of the same elemental composition of the compound. Polymorphs generally have different X-ray diffraction spectra, infrared spectra, melting points, density, hardness, crystal form, optical and electrical properties, stability and solubility. Different factors such as recrystallization solvent, crystallization rate and storage temperature may cause a single crystalline form to dominate.
[0125] In another aspect, compounds of formula (1) may have chiral centers and / or axial chirality and thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric compounds and single diastereomers, and cis-trans isomers. Each chiral center or axial chirality will independently produce two optical isomers, and all possible optical isomers and diastereomeric mixtures as well as pure or partially purified compounds are included within the scope of the present invention. The present invention is meant to include all such isomeric forms of these compounds.
[0126] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125 ( 125 I) and C-14( 14 C). For example, deuterated compounds can be formed by replacing hydrogen atoms with heavy hydrogen. The bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs generally have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged drug half-life in vivo. All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of this invention.
[0127] Unless otherwise specified, any reference to an atom in the compounds of the present invention refers to its stable atomic isotope. Unless otherwise specified, when a position in a molecular structure is designated as "H" or "hydrogen," such position should be understood to have the natural abundance of the hydrogen isotope. Similarly, when a position is designated as "D" or "deuterium," such position should be understood to have a deuterium isotope abundance at least 3000 times its natural abundance (the natural abundance of the deuterium isotope is 0.015%).
[0128] More preferably, the deuterium atom abundance at each deuterated site of the deuterated compound of the present invention is at least 3500 times its natural abundance (52.2% deuterium atom enrichment). More preferably, it is at least 4500 times (67.5% deuterium atom enrichment). More preferably, it is at least 5000 times (75% deuterium atom enrichment). More preferably, it is at least 6000 times (90% deuterium atom enrichment). More preferably, it is at least 6333 times (95% deuterium atom enrichment). More preferably, it is at least 6466.7 times (97% deuterium atom enrichment). More preferably, it is at least 6600 times (99% deuterium atom enrichment). More preferably, it is at least 6633.3 times (99.5% deuterium atom enrichment).
[0129] the term
[0130] Unless otherwise indicated, the terms used in this application, including the specification and claims, are defined as follows. It should be noted that, throughout the specification and the appended claims, the singular forms "a," "an," and "an" include plural referents unless the context clearly indicates otherwise. Conventional methods, such as mass spectrometry, nuclear magnetic resonance, HPLC, protein chemistry, biochemistry, recombinant DNA technology, and pharmacology, are employed unless otherwise indicated. Throughout this application, the use of "or" or "and" means "and / or," unless otherwise indicated.
[0131] Unless otherwise specified, "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight and branched groups of 1 to 6 carbon atoms. Preferred are lower alkyl groups containing 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl, and tert-butyl. More preferred are lower alkyl groups containing 1 to 3 carbon atoms, such as methyl, ethyl, propyl, and 2-propyl. As used herein, "alkyl" includes unsubstituted and substituted alkyl groups, especially alkyl groups substituted with one or more halogens. Preferred alkyl groups are selected from CH3, CH3CH2, CF3, CHF2, CF3CH2, CF3(CH3)CH, i Pr, n Pr, i Bu, n Bu or t Bu.
[0132] Unless otherwise specified, "alkylene" refers to a divalent alkyl group as defined above. Examples of alkylene groups include, but are not limited to, methylene and ethylene.
[0133] Unless otherwise specified, "alkenyl" refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon double bond, including straight or branched groups of 1 to 14 carbon atoms. Preferred are lower alkenyl groups containing 1 to 4 carbon atoms, such as ethenyl, 1-propenyl, 1-butenyl, or 2-methylpropenyl. More preferred are lower alkenyl groups containing 1 to 2 carbon atoms.
[0134] Unless otherwise specified, "alkenylene" refers to a divalent alkenyl group as defined above.
[0135] Unless otherwise specified, "alkynyl" refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon triple bond, including straight-chain and branched groups having 1 to 14 carbon atoms. Preferred are lower alkynyl groups having 1 to 4 carbon atoms, such as ethynyl, 1-propynyl, or 1-butynyl. More preferred are lower alkynyl groups having 1 to 2 carbon atoms.
[0136] Unless otherwise specified, "alkynylene" refers to a divalent alkynyl group as defined above.
[0137] Unless otherwise specified, "cycloalkyl" refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic), preferably containing 3 to 14 ring carbon atoms (C 3-14 In some embodiments, the cycloalkyl group has 3-10 ring carbon atoms (C 3-10 In some embodiments, a cycloalkyl group has 3-8 ring carbon atoms (C 3-8 In some embodiments, the cycloalkyl group has 3-7 ring carbon atoms (C 3-7 In some embodiments, the cycloalkyl group has 3-6 ring carbon atoms (C 3-6 In some embodiments, the cycloalkyl group has 4-6 ring carbon atoms (C 4-6 In some embodiments, the cycloalkyl group has 5-6 ring carbon atoms (C 5-6 In some embodiments, a cycloalkyl group has 5-10 ring carbon atoms (C 5-10Cycloalkyl). If the carbocyclic ring contains at least one double bond, the partially unsaturated cycloalkyl group may be referred to as a "cycloalkenyl group," or if the carbocyclic ring contains at least one triple bond, the partially unsaturated cycloalkyl group may be referred to as a "cycloalkynyl group." Cycloalkyl groups may include monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) groups and spirocycles. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is bicyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is tricyclic. The ring-forming carbon atoms of the cycloalkyl group may optionally be oxidized to form an oxo or thio group. Cycloalkyl groups also include cycloalkylene groups. In some embodiments, the cycloalkyl group contains 0, 1, or 2 double bonds. In some embodiments, the cycloalkyl group contains 1 or 2 double bonds (partially unsaturated cycloalkyl groups). In some embodiments, the cycloalkyl group may be fused with an aryl group, a heteroaryl group, a cycloalkyl group, and a heterocycloalkyl group. In some embodiments, the cycloalkyl group may be fused with an aryl group, a cycloalkyl group, and a heterocycloalkyl group. In some embodiments, cycloalkyl groups can be fused with aryl groups and heterocycloalkyl groups. In some embodiments, cycloalkyl groups can be fused with aryl groups and cycloalkyl groups. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcaryl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl, and the like.
[0138] Unless otherwise specified, "cycloalkylene" refers to a divalent cycloalkyl group as defined above.
[0139] Unless otherwise specified, "alkoxy" refers to an alkyl group bonded to the rest of the molecule through an ether oxygen atom. Representative alkoxy groups are those having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy. As used herein, "alkoxy" includes unsubstituted and substituted alkoxy groups, especially those substituted with one or more halogens. Preferred alkoxy groups are selected from OCH3, OCF3, CHF2O, CF3CH2O, i- PrO, n- PrO, i- BuO, n- BuO or t- BuO.
[0140] Unless otherwise specified, "aryl" refers to a hydrocarbon aromatic group. Aryl is monocyclic or polycyclic, for example, a monocyclic aryl ring fused to one or more carbocyclic aromatic groups. Examples of aryl include, but are not limited to, phenyl, naphthyl, and phenanthrenyl.
[0141] Unless otherwise specified, "aryloxy" refers to an aryl group bonded to the rest of the molecule through an ethereal oxygen atom. Examples of aryloxy groups include, but are not limited to, phenoxy and naphthoxy.
[0142] Unless otherwise specified, "arylene" refers to a divalent aromatic radical as defined above. Examples of arylene groups include, but are not limited to, 1,4-phenylene, 1,3-phenylene, 1,2-phenylene, naphthylene, and phenanthrenylene.
[0143] Unless otherwise specified, "heteroaryl" refers to a substituted or unsubstituted aromatic group containing one or more heteroatoms, the heteroatoms being independently selected from O, N or S, preferably 1, 2, 3 or 4 heteroatoms, preferably a 5-14 membered aromatic group containing 1-4 heteroatoms selected from oxygen, sulfur and nitrogen, more preferably a 5-9 membered aromatic group containing 1-2 heteroatoms selected from oxygen, sulfur or nitrogen, more preferably a 5-6 membered aromatic group containing 1-3 heteroatoms selected from oxygen, sulfur or nitrogen. The heteroaryl group is monocyclic or polycyclic. The monocyclic heteroaryl group is preferably a 5-6 membered aromatic group containing 1-3 heteroatoms selected from oxygen, nitrogen or sulfur. More preferably, it is a 5-6 membered aromatic group containing 1-2 heteroatoms selected from oxygen, nitrogen or sulfur. More preferably, it is a 5-6 membered aromatic group containing 1 heteroatom selected from oxygen, nitrogen or sulfur. In some embodiments, the monocyclic heteroaryl ring is fused with one or more carbocyclic aromatic groups or other monocyclic heterocycloalkyl groups. Examples of heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, quinazolinyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzopyridinyl, pyrrolopyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-c]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl,
[0144] Unless otherwise specified, "heteroarylene" refers to a divalent heteroaryl group as defined above.
[0145] Unless otherwise specified, "heterocycloalkyl" refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, having at least one heteroatom ring member independently selected from boron, phosphorus, nitrogen, sulfur, oxygen and selenium, preferably a saturated or partially unsaturated ring containing 1-4 heteroatoms selected from oxygen, sulfur or nitrogen, more preferably a saturated or partially unsaturated ring containing 1-2 heteroatoms selected from oxygen, sulfur or nitrogen. In some embodiments, heterocycloalkyl is a 5-14 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen or sulfur (5-14 membered heterocycloalkyl). In some embodiments, heterocycloalkyl is a 3-9 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen or sulfur (3-9 membered heterocycloalkyl). In some embodiments, heterocycloalkyl is a 5-8 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (5-8 membered heterocycloalkyl). In some embodiments, heterocycloalkyl is a 5-6 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (5-6 membered heterocycloalkyl). In some embodiments, 5-6 membered heterocycloalkyl contains 1-3 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, 5-6 membered heterocycloalkyl contains 1-2 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, 5-6 membered heterocycloalkyl contains 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, heterocycloalkyl is a 10-13 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (10-13 membered heterocycloalkyl). In some embodiments, 10-13 membered heterocycloalkyl groups contain 1-3 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, 10-13 membered heterocycloalkyl groups contain 1-2 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, 10-13 membered heterocycloalkyl groups contain 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. If the heterocycloalkyl group contains at least one double bond, the partially unsaturated heterocycloalkyl group may be referred to as a "heterocycloalkenyl group," or if the heterocycloalkyl group contains at least one triple bond, the partially unsaturated heterocycloalkyl group may be referred to as a "heterocycloalkynyl group." Heterocycloalkyl groups may include monocyclic, bicyclic, spirocyclic, or polycyclic (e.g., having two fused or bridged rings) ring systems. In some embodiments, heterocycloalkyl groups are monocyclic groups having 1, 2, or 3 heteroatoms independently selected from nitrogen, sulfur, and oxygen. The ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group may be optionally oxidized to form oxo or thio or other oxidized bonds (e.g., C(O), S(O), C(S) or S(O) 2, N-oxide, etc.), or the nitrogen atom may be quaternized. The heterocycloalkyl group may be connected via ring-forming carbon atoms or ring-forming heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds.In some embodiments, heterocycloalkyl contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties (also referred to as partially unsaturated heterocycles) with one or more aromatic rings fused to the heterocycloalkyl ring (i.e., sharing a key therewith), such as benzo derivatives of piperidine, morpholine, azacycloheptane or tetrahydrothienyl, and pyrido derivatives of piperidine, morpholine, azacycloheptane or tetrahydrothienyl. Heterocycloalkyl containing fused aromatic rings can be connected via any ring-forming atoms, including ring-forming atoms of the fused aromatic ring. Examples of heterocycloalkyl groups include, but are not limited to, azetidinyl, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, N-morpholinyl, 3-oxa-9-azaspiro[5.5]undecyl, 1-oxa-8-azaspiro[4.5]decyl, piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl, quinuclyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, tropanediyl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinyl, 4,5,6,7-tetrahydro-1H-imidazole , 4-nitro-2-nitro-1-pyridine, 4 ...1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine,
[0146] Unless otherwise specified, "heterocycloalkylene" refers to a divalent heterocycloalkyl group as defined above.
[0147] Unless otherwise specified, "oxo" refers to =0; for example, a carbonyl group substituted with an oxo group is a "carbonyl group." "; the group formed by sulfur being replaced by an oxo group is called "sulfinyl" ", the group formed by sulfur being substituted by two oxo groups is called "sulfonyl" ”.
[0148] Unless otherwise specified, "halogen" (or halo) refers to fluorine, chlorine, bromine or iodine. The term "halo" (or "halogen substituted") appearing before the name of a group indicates that the group is partially or fully halogenated, that is, substituted by F, Cl, Br or I in any combination, preferably substituted by F or Cl.
[0149] Unless otherwise specified, the term "substituted" refers to a substituent group other than one or more hydrogen atoms on a specified atom or group that is substituted by one or more hydrogen atoms, without exceeding the normal valence of the specified atom. For example, one or more hydrogen atoms of an alkyl, alkylene, alkenyl, alkynyl, hydroxyl or amido group can be substituted by one or more substituent groups. Wherein the substituent group includes but is not limited to alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxylate, cyano, guanidino, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclic radical, hydroxyl, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, mercaptan, thioketone or its combination. The definition of "substituted" does not include similar indefinite structures obtained by defining a substituent group having a further substituent group attached to infinity (for example, a substituted aryl group itself substituted by a substituted aryl group with a substituted alkyl group, which is further substituted by a substituted heteroalkyl group, etc.). Unless otherwise specified, the maximum number of consecutive substitutions in the compounds described herein is three. For example, a substituted aryl group is continuously substituted by two other substituted aryls to an aryl group substituted by ((substituted aryl) substituted aryl). Similarly, the above definition does not include substitution patterns that are not allowed (for example, a methyl group substituted by 5 fluorines or a heteroaryl group with two adjacent oxygen ring atoms). This substitution pattern that is not allowed is well known to those skilled in the art. Whenever used to modify a chemical group, "substituted" can describe other chemical groups defined herein. For example, the term "substituted aryl" includes but is not limited to "alkyl aryl". Unless otherwise specified, if a group is described as optionally substituted, any substituent of the group itself is unsubstituted.
[0150] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0151] Unless otherwise specified, "acyl" refers to -C(=O)-R, where R is selected from optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heterocycloalkyl.
[0152] Unless otherwise specified, it will be understood that the word "comprise", or variations such as "comprises" or "comprising", imply the inclusion of a stated element or integer, or group of elements or integers, but not the exclusion of any other element or integer, or group of elements or integers.
[0153] The substituent "-O-CH2-O-" refers to the substituent in which two oxygen atoms are connected to two adjacent carbon atoms of a heterocycloalkyl, aryl or heteroaryl group, for example:
[0154] When the number of a linking group is 0, such as -(CH2)0-, it means that the linking group is a single bond.
[0155] When one of the variables is selected from a chemical bond, it means that the two groups it connects are directly connected. For example, when L in XLY represents a chemical bond, it means that the structure is actually XY.
[0156] The term "membered ring" includes any cyclic structure. The term "membered" refers to the number of atoms that make up the ring. For example, cyclohexyl, pyridyl, pyranyl, and thiopyranyl are six-membered rings, while cyclopentyl, pyrrolyl, furanyl, and thiophenyl are five-membered rings.
[0157] The term "fragment" refers to a specific part or functional group of a molecule. A chemical fragment is generally considered to be a chemical entity contained in or attached to a molecule.
[0158] The term "isomer" means any tautomer, stereoisomer, atropisomer, isotopomer, enantiomer or diastereomer of any compound of the present invention. The compounds of the present invention may have one or more chiral centers or double bonds and therefore exist in stereoisomeric form, for example, as double bond isomers (i.e., E / Z geometric isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis / trans isomers). Therefore, the compounds of the present invention encompass all corresponding stereoisomers, i.e., stereoisomerically pure (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) forms as well as enantiomers and stereoisomer mixtures, such as racemates. Enantiomeric and stereoisomeric mixtures of the compounds of the present invention can be separated into their component enantiomers or stereoisomers by well-known methods, such as chiral gas chromatography, chiral high performance liquid chromatography, and crystallization of the compounds as chiral salt complexes or crystallization of the compounds in chiral solvents. Enantiomers and stereoisomers can also be obtained from stereoisomerically pure or enantiomerically pure intermediates, reagents and catalysts by well-known asymmetric synthetic methods.
[0159] The term "isotopomers" refers to molecules that differ in structure only in their isotopes but are otherwise identical in structure.
[0160] The term "atropisomer" refers to a conformational stereoisomer produced when rotation about a single bond within a molecule is prevented or greatly slowed due to steric interactions with other parts of the molecule and the substituents at either end of the single bond are asymmetric, i.e., atropisomers do not require a stereocenter. When the barrier to rotation about the single bond is sufficiently high and the interconversion between conformations is sufficiently slow, separation of the individual isomers is permitted (LaPlante et al., J. Med. Chem. 2011, 54, 20, 7005), preferably by chiral resolution.
[0161] Unless otherwise specified, use a solid wedge key. and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond and straight dashed key Indicate the relative configuration of stereocenters with a wavy line Indicates a wedge-shaped solid key or dotted wedge key Or use a wavy line Indicates a straight solid bond or straight dashed key
[0162] Unless otherwise stated, Indicates a single bond or a double bond.
[0163] Specific pharmaceutical and medical terms
[0164] The term "acceptable," as used herein, means that a prescribed ingredient or active ingredient has no undue adverse effect on health and well-being for the general purpose of treatment.
[0165] The terms "treat," "treatment," or "therapy" as used herein include alleviating, inhibiting, or ameliorating the symptoms of a disease or condition; inhibiting the development of complications; ameliorating or preventing underlying metabolic syndrome; inhibiting the development of a disease or symptom, such as controlling the progression of a disease or condition; alleviating a disease or symptom; causing a regression of a disease or symptom; alleviating complications caused by a disease or symptom, or preventing or treating signs caused by a disease or symptom. As used herein, a compound or pharmaceutical composition, upon administration, can improve a disease, symptom, or condition, particularly by improving its severity, delaying its onset, slowing its progression, or reducing its duration. Whether the administration is fixed or temporary, continuous or intermittent, the circumstances attributable to or related to the administration can be explained.
[0166] "Active ingredient" refers to the compound of formula (1), as well as pharmaceutically acceptable inorganic or organic salts of the compound of formula (1). The compounds of the present invention may contain one or more asymmetric centers (chiral centers or axial chirality) and therefore appear in the form of racemates, racemic mixtures, single enantiomers, diastereomeric compounds and single diastereomers. The asymmetric centers that may exist depend on the properties of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and all possible optical isomers and diastereomeric mixtures as well as pure or partially pure compounds are included within the scope of the present invention. The present invention is meant to include all such isomeric forms of these compounds.
[0167] The terms "compound," "composition," "agent," or "medicine or medicament" are used interchangeably herein and refer to a compound or composition that, when administered to a subject (human or animal), induces a desired pharmaceutical and / or physiological response through local and / or systemic action.
[0168] The term "administered," "administering," or "administration" as used herein refers to the direct administration of the compound or composition, or the administration of a prodrug, derivative, or analog of the active compound.
[0169] Although the numerical ranges and parameters used to define the broader scope of the present invention are approximate, the numerical values of the specific examples are presented herein as precisely as possible. However, any numerical value inherently and inevitably contains standard deviations resulting from individual testing methods. As used herein, "about" generally refers to the actual value being within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "about" means that the actual value falls within an acceptable standard error of the mean, as determined by one skilled in the art. Except in the experimental examples, or unless otherwise expressly indicated, all ranges, amounts, values, and percentages used herein (e.g., to describe material amounts, time periods, temperatures, operating conditions, quantitative ratios, and the like) are to be understood as modified by the word "about." Therefore, unless otherwise indicated, the numerical parameters disclosed in this specification and the appended claims are approximate and may be modified as needed. At a minimum, these numerical parameters should be understood to include the number of significant digits indicated and to include normal rounding.
[0170] Unless otherwise defined in this specification, the scientific and technical terms used herein have the same meanings as commonly understood by those skilled in the art. In addition, unless otherwise defined in this specification, singular terms used in this specification include the plural form of the term, and plural terms also include the singular form of the term, unless otherwise defined in the context.
[0171] Therapeutic uses
[0172] The compounds of formula (1) or pharmaceutical compositions of the present invention are generally useful for inhibiting DGKζ protein, and thus can be used to treat one or more conditions associated with DGKζ protein activity. Therefore, in certain embodiments, the present invention provides a method for treating a condition mediated by DGKζ protein, comprising administering to a patient in need thereof a compound of formula (1) or a pharmaceutically acceptable composition thereof.
[0173] In some embodiments, a method for treating cancer is provided, comprising administering to a subject in need thereof an effective amount of any of the aforementioned pharmaceutical compositions comprising a compound of formula (1). In some embodiments, the cancer includes, but is not limited to, hematological malignancies (leukemia, lymphoma, myeloma including multiple myeloma, myelodysplastic syndrome, and myeloproliferative syndrome) and solid tumors (cancers such as prostate, breast, lung, colon, pancreas, kidney, ovary, and soft tissue cancer and osteosarcoma, as well as stromal tumors). Preferably, the cancer is head and neck cancer, kidney cancer, ovarian cancer, intestinal cancer, urothelial carcinoma, melanoma, liver cancer, gastric cancer, lung cancer, bladder cancer, and cancer metastasis thereof.
[0174] Route of administration
[0175] The compounds of the present invention and their pharmaceutically acceptable salts can be formulated into various formulations containing a safe and effective amount of the compounds of the present invention or their pharmaceutically acceptable salts and a pharmacologically acceptable excipient or carrier. "Safe and effective amount" means an amount of the compound sufficient to significantly improve the condition without causing serious side effects. The safe and effective amount of the compound will be determined based on the patient's age, condition, and duration of treatment, among other factors.
[0176] "Pharmaceutically acceptable excipients or carriers" refer to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmacologically acceptable excipients or carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0177] The compounds of the present invention may be administered orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously), or topically.
[0178] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0179] Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such compositions can be delayed in a certain portion of the digestive tract. Examples of useful encapsulating components are polymeric substances and waxes. If desired, the active compound can also be microencapsulated with one or more of the above-mentioned excipients.
[0180] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures thereof.
[0181] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0182] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.
[0183] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0184] Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
[0185] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds. When using a pharmaceutical composition, a safe and effective amount of the compounds of the present invention is applied to a mammal (e.g., a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage. For a 60 kg human, the daily dosage is generally 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health status, all of which are within the skill of a skilled physician.
[0186] The features described above, or in the embodiments, may be combined in any combination. All features disclosed in this specification may be used in any combination, and each feature disclosed in this specification may be replaced by any alternative feature that serves the same, equivalent, or similar purpose. Therefore, unless otherwise specified, the features disclosed are merely general examples of equivalent or similar features. DETAILED DESCRIPTION
[0187] The following description will elaborate on various specific aspects, characteristics, and advantages of the above-mentioned compounds, methods, and pharmaceutical compositions so that the present invention will be readily apparent. It should be understood that the following detailed description and examples describe specific embodiments and are provided for reference only. After reading the present description, those skilled in the art may make various changes or modifications to the present invention, and such equivalents are within the scope of the present invention.
[0188] In all embodiments, 1 H-NMR was recorded on a Varian Mercury 400 nuclear magnetic resonance instrument, and chemical shifts are expressed in δ (ppm). Silica gel used for separation was 200-300 mesh unless otherwise specified, and the eluent ratios were all by volume.
[0189] The present invention uses the following abbreviations: (Boc)2O represents di-tert-butyl dicarbonate; CDCl3 represents deuterated chloroform; Cs2CO3 represents cesium carbonate; EtOAc represents ethyl acetate; Hexane represents n-hexane; HPLC represents high performance liquid chromatography; MeCN represents acetonitrile; DCM represents dichloromethane; DIPEA represents diisopropylethylamine; Dioxane represents 1,4-dioxane; DME represents ethylene glycol dimethyl ether; DMF represents N,N-dimethylformamide; DMAP represents 4-(dimethylamino)pyridine; DMSO represents dimethyl sulfoxide; EtOH represents ethanol; hr represents hour; IPA represents isopropyl alcohol; =Biotage Isolera Prime rapid preparative liquid chromatograph; min = minute; K2CO3 = potassium carbonate; KOAc = potassium acetate; KOH = potassium hydroxide; K3PO4 = potassium phosphate; LiBH4 = lithium borohydride; min = minute; MeOH = methanol; MeONa = sodium methoxide; MS = mass spectrometry; NaBH(OAc)3 = sodium triacetoxyborohydride; NaH = sodium hydrogen; NMR = nuclear magnetic resonance; NIS = iodosuccinimide; Pd / C = palladium on carbon; Pd(PPh3)4 = tetraphenylethylene Phosphine palladium; Pd(OAc)2 represents palladium acetate; Pd(dppf)Cl2 represents [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride; PE represents petroleum ether; PPh3 represents triphenylphosphine; TEA represents triethylamine; TFA represents trifluoroacetic acid; TsOH represents p-toluenesulfonic acid; XantPhos represents 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; TfOH represents trifluoromethanesulfonic acid; TLC represents thin layer chromatography; XPhos represents 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl.
[0190] Example 1 Synthesis of Compound 16
[0191] Step 1: Synthesis of compound int_16-2:
[0192] Int_16-1 (15.3 g, 0.1 mol), THF (200 mL), and cyanamide (4.2 g, 0.1 mol) were added to a 500 mL single-necked flask. NaOEt (6.8 g, 0.1 mol) was added portionwise to the mixture under argon. The mixture was stirred at room temperature under argon for 1-2 hours. After completion of the reaction, monitored by LC-MS, the resulting solution was used directly in the next step.
[0193] ESI-MS m / z:196[M+H] +
[0194] Step 2: Synthesis of compound int_16-4:
[0195] To the reaction mixture from step 1, int_16-3 (22.3 g, 0.1 mol) was added. The mixture was stirred at room temperature under argon for 20 h. LC-MS analysis indicated that the reaction was nearly complete. The mixture was then concentrated under reduced pressure to obtain the crude product. This crude product was used directly in the next step (33 g).
[0196] ESI-MS m / z:338[M+H] +
[0197] Step 3: Synthesis of compound int_16-5:
[0198] To a 1-L single-necked flask, int_16-4 (33 g, crude product, 0.1 mol), DCM (400 mL), DIPEA (32.3 g, 0.25 mol), and DMAP (2.44 g, 0.02 mol) were added. BocO (21.6 g, 0.1 mol) was added at room temperature under argon. The mixture was stirred at room temperature for 72 hours. After completion of the reaction, as monitored by LC-MS, water (200 mL) was added, stirred, and the layers separated. The organic phase was washed with saturated sodium chloride solution and concentrated. The residue was purified by column chromatography to afford the product as a light brown solid (25 g, 57% yield).
[0199] ESI-MS m / z:438[M+H] +
[0200] Step 4: Synthesis of compound 16:
[0201] Int_16-5 (56 mg, 0.128 mmol), DMF (2 mL), KCO (36 mg, 0.261 mmol), NaI (20 mg, 0.133 mmol), and 2-chloropropionamide (16 mg, 0.149 mmol) were added to a 25 mL single-necked vial. The mixture was heated to 120°C under argon for 1 h. The product was detected by LC-MS. The mixture was then flash purified to afford a light brown solid (45 mg, 86% yield).
[0202] ESI-MS m / z:409[M+H] +
[0203] Example 2 Synthesis of Compound 17 and Compound 18
[0204] Compound 16 (143 mg, 0.35 mmol) was subjected to SFC chiral separation (condition: column: DAICEL CHIRALCEL OD-H (250 mm*30 mm, 5 um); mobile phase: [0.1% NH3H2O MeOH]; B%: 40%-40%, min) to give compound 17 (peak 1, 50 mg, yield: 34%) and compound 18 (peak 2, 50 mg, yield: 34%).
[0205] Compound 17: MS (ESI): 409 [M+H] + .
[0206] Compound 18: MS (ESI): 409 [M+H] + .
[0207] Example 3 Synthesis of Compound 48
[0208] Step 1: Synthesis of compound int_48-2:
[0209] Int_16-2 (3 g, 15.36 mmol), int_48-1 (4.69 g, 16.89 mmol), and sodium ethoxide (3.1 g, 46.08 mmol) were dissolved in tetrahydrofuran (150 mL). The mixture was stirred at room temperature under argon for 20 hours. After completion of the reaction, the mixture was concentrated under reduced pressure by LC-MS to obtain the crude product, which was then purified by column chromatography to afford a solid product (5.5 g, 91.6% yield).
[0210] ESI-MS m / z:392[M+H] + .
[0211] Step 2: Synthesis of compound int_48-3:
[0212] Int_48-2 (800 mg, 2.03 mmol), KCO (704 mg, 5.09 mmol), NaI (456 mg, 3.04 mmol), and 2-chloropropionamide (240 mg, 2.23 mmol) were dissolved in DMF (30 mL). The mixture was heated to 120°C under argon for 1 hour. LC-MS monitored the reaction completion. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford a solid product (735 mg, 78.1% yield).
[0213] ESI-MS m / z:463[M+H] + .
[0214] Step 3: Synthesis of compound 48:
[0215] Int_48-3 (500 mg, 1.07 mmol), K3PO4 (687 mg, 3.23 mmol), Pd(dppf)Cl2 (73 mg, 0.1 mmol), and int_48-4 (337 mg, 1.6 mmol) were dissolved in a mixture of 1,4-dioxane (20 mL) and water (2 mL). The mixture was heated to 100°C under argon for 3 hours. LC-MS monitored the reaction completion. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford a solid product (377 mg, 75.5% yield).
[0216] ESI-MS m / z:467[M+H] +
[0217] Example 4 Synthesis of Compound 102 and Compound 103
[0218] Compound 48 (200 mg, 0.42 mmol) was subjected to SFC chiral separation to obtain compound 102 (72 mg, yield: 36%) and compound 103 (73 mg, yield: 36.5%).
[0219] Compound 102: MS (ESI): 467 [M+H] + .
[0220] Compound 103: MS (ESI): 467 [M+H] + .
[0221] Example 5 Synthesis of Compound 46
[0222] Step 1: Synthesis of compound 46:
[0223] Compound 48 (500 mg, 1.07 mmol) and Pd / C (10%, 5 g) were dissolved in tetrahydrofuran (50 mL). The reaction mixture was replaced with hydrogen three times and stirred at room temperature under a hydrogen atmosphere for 48 hours. LC-MS monitored the reaction completion. The mixture was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography to afford a solid product (350 mg, 69.8% yield).
[0224] ESI-MS m / z:469[M+H] + .
[0225] Example 6 Synthesis of Compound 60
[0226] Step 1: Synthesis of compound int_60-3:
[0227] Under nitrogen, int_60-1 (10 g, 64.93 mmol) was dissolved in tetrahydrofuran (200 mL). The mixture was cooled to -78°C and LDA (2 M, 32.46 mL, 64.93 mmol) was slowly added dropwise to the reaction mixture. The reaction was stirred at -78°C for 0.5 hour. Then, int_60-2 (14.23 g, 97.39 mmol) was slowly added dropwise to the reaction mixture. The reaction mixture was stirred at -78°C for another 2 hours and then slowly warmed to room temperature. LC-MS monitored the reaction completion. Saturated ammonium chloride was added to the reaction mixture, and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to obtain a solid product (7.8 g, yield: 47.3%).
[0228] ESI-MS m / z:254[M+H] + .
[0229] Step 2: Synthesis of compound int_60-5:
[0230] Int_60-3 (7.8 g, 30.69 mmol) and int_60-4 (3.41 g, 30.69 mmol) were dissolved in DMF (200 mL). The mixture was reacted under argon at room temperature for 12 hours. LC-MS monitored the reaction completion. The reaction mixture was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography to afford a solid product (6.5 g, 65.0% yield).
[0231] ESI-MS m / z:329[M+H] + .
[0232] Step 3: Synthesis of compound int_60-6:
[0233] Int_60-5 (6 g, 18.25 mmol) and lithium hydroxide monohydrate (1.53 g, 36.50 mmol) were dissolved in a mixture of THF (100 mL) and water (50 mL). The reaction mixture was allowed to react at room temperature for 12 hours. LC-MS monitored the reaction completion. The pH of the reaction mixture was adjusted to 2-3 with dilute hydrochloric acid. The reaction mixture was filtered and the filter cake was collected and dried to obtain a solid product (5 g, yield: 91.2%).
[0234] ESI-MS m / z:301[M+H] + .
[0235] Step 4: Synthesis of compound int_60-7:
[0236] Dissolve int_60-6 (5 g, 16.62 mmol) in DCM (100 mL). Slowly add oxalyl chloride (4.2 g, 32.25 mmol) and two drops of DMF. The reaction mixture is allowed to react at room temperature for 2 hours. The reaction mixture is concentrated under reduced pressure to obtain the crude product (5 g).
[0237] Step 5: Synthesis of compound int_60-9:
[0238] Int_60-7 (5 g, 15.66 mmol), int_60-8 (2.71 g, 18.80 mmol), and triethylamine (4.75 g, 46.98 mmol) were dissolved in DCM (150 mL). The reaction mixture was heated to 50°C for 12 hours. After completion of the reaction, the mixture was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography to afford a solid product (5.1 g, 79.6% yield).
[0239] ESI-MS m / z:409[M+H] + .
[0240] Step 6: Synthesis of compound int_60-10:
[0241] Int_60-9 (1 g, 2.44 mmol), KCO (676 mg, 4.89 mmol), NaI (548 mg, 3.66 mmol), and 2-chloropropionamide (314 mg, 2.92 mmol) were dissolved in DMF (60 mL). The mixture was heated to 120°C under argon for 1 hour. LC-MS monitored the reaction completion. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford a solid product (650 mg, 55.5% yield).
[0242] ESI-MS m / z:480[M+H] +
[0243] Step 7: Synthesis of compound 60:
[0244] Int_60-10 (650 mg, 1.35 mmol) was dissolved in methanol (5 mL). A 7N methanolic ammonia solution (20 mL) was added, and the mixture was allowed to react at room temperature for 16 hours. LC-MS monitored the reaction completion. The reaction solution was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography to afford a solid product (450 mg, 72.2% yield).
[0245] 1 H NMR (400MHz, DMSO-d6) δ8.73(d,J=10.7Hz,2H),7.68(dd,J=8.8,4.9Hz,2H),7.61(s,1H),7.38(t,J=8.5Hz,2H),7.28(s,1H),5.11(s,1H),3.8 1(d,J=11.2Hz,2H),3.42(t,J=11.2Hz,2H),3.13–3.03(m,1H),1.80(d,J=13.3Hz,2H),1.59(d,J=12.3Hz,2H),1.17(d,J=7.4Hz,3H).; ESI-MS m / z:461[M+H] +
[0246] Example 7 Synthesis of Compound 61 and Compound 62
[0247] Compound 60 (300 mg, 0.65 mmol) was subjected to SFC chiral separation to obtain compound 61 (110 mg, yield: 36.6%) and compound 62 (100 mg, yield: 33.3%).
[0248] Compound 61: MS (ESI): 461 [M+H] + .
[0249] Compound 62: MS (ESI): 461 [M+H] + .
[0250] Example 8 Synthesis of Compound 72
[0251] Step 1: Synthesis of compound int_72-2:
[0252] Int_16-2 (3 g, 15.36 mmol), int_72-1 (6.6 g, 30.72 mmol), and sodium ethoxide (3.1 g, 46.08 mmol) were dissolved in tetrahydrofuran (200 mL). The mixture was stirred at room temperature under argon for 20 hours. After completion of the reaction, the mixture was concentrated under reduced pressure by LC-MS to obtain the crude product, which was then purified by column chromatography to afford a solid product (4.3 g, 86% yield).
[0253] ESI-MS m / z:330[M+H] + .
[0254] Step 2: Synthesis of compound int_72-3:
[0255] Int_72-2 (1 g, 3.03 mmol), (Boc)2O (1.3 g, 6.07 mmol), DMAP (36 mg, 0.3 mmol), and DIPEA (1.17 g, 9.09 mmol) were dissolved in dichloromethane (50 mL). The mixture was reacted under argon at room temperature for 72 hours. LC-MS monitored the reaction completion. The reaction mixture was concentrated under reduced pressure to obtain the crude product, which was then purified by column chromatography to afford a solid product (1.1 g, 84.6% yield).
[0256] ESI-MS m / z:430[M+H] + .
[0257] Step 3: Synthesis of compound int_72-5:
[0258] Int_72-3 (650 mg, 1.51 mmol), K2CO3 (418 mg, 3.02 mmol), and int_72-4 (224 mg, 1.66 mmol) were dissolved in DMF (20 mL). The mixture was reacted at room temperature under argon for 3 hours. LC-MS monitored the reaction completion. Water (50 mL) was added to the reaction solution, and the aqueous phase was extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford a solid product (550 mg, 95.1% yield).
[0259] ESI-MS m / z:384[M+H] + .
[0260] Step 4: Synthesis of compound 72:
[0261] Int_72-5 (766 mg, 2 mmol), KCO (704 mg, 5.09 mmol), NaI (456 mg, 3.04 mmol), and 2-chloropropionamide (240 mg, 2.23 mmol) were dissolved in DMF (30 mL). The mixture was heated to 120°C under argon for 1 hour. LC-MS monitored the reaction completion. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford a solid product (790 mg, 86.9% yield).
[0262] ESI-MS m / z:455[M+H] + .
[0263] Example 9 Synthesis of Compound 73 and Compound 74
[0264] Compound 72 (350 mg, 0.77 mmol) was subjected to SFC chiral separation to obtain compound 73 (79 mg, yield: 22.5%) and compound 74 (88 mg, yield: 25.1%).
[0265] Compound 73: MS (ESI): 467 [M+H] + .
[0266] Compound 74: MS (ESI): 467 [M+H] + .
[0267] Example 10 Synthesis of Compound 82
[0268] Step 1: Synthesis of compound int_82-2:
[0269] Dissolve int_16-2 (3 g, 15.36 mmol), int_82-1 (4.7 g, 16.89 mmol), and sodium ethoxide (3.1 g, 46.08 mmol) in tetrahydrofuran (150 mL). Stir the mixture under argon at room temperature for 20 hours. After completion of the reaction, monitored by LC-MS, the mixture was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford 5.1 g of a solid product (yield: 85%).
[0270] ESI-MS m / z:393[M+H] + .
[0271] Step 2: Synthesis of compound int_82-3:
[0272] Int_82-2 (1.1 g, 2.79 mmol), KCO (1.15 g, 8.39 mmol), NaI (1.04 g, 6.97 mmol), and 2-chloropropionamide (330 mg, 3.06 mmol) were dissolved in DMF (30 mL). The mixture was heated to 120°C under argon for 1 hour. LC-MS monitored the reaction completion. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford a solid product (720 mg, 55.5% yield).
[0273] ESI-MS m / z:463[M+H] + .
[0274] Step 3: Synthesis of compound 82:
[0275] Int_82-3 (500 mg, 1.07 mmol), K3PO4 (687 mg, 3.23 mmol), Pd(dppf)Cl2 (73 mg, 0.1 mmol), and int_82-4 (545 mg, 2.67 mmol) were dissolved in a mixture of 1,4-dioxane (30 mL) and water (3 mL). The mixture was heated to 100°C under argon and reacted for 3 hours. LC-MS monitored the reaction completion. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography to afford a solid product (410 mg, yield: 83.1%).
[0276] 1 H NMR (400MHz, DMSO-d6) δ8.75(dd,J=2.2,1.0Hz,1H),8.09–8.04(m,2H),7.98(dd,J=8.3,1.0Hz,1H),7.93(dd,J=8.2,2.3Hz,1H),7.64(dd,J =8.8,5.0Hz,2H),7.57(s,1H),7.50–7.41(m,3H),7.31(t,J=8.8Hz,2H),7.24(s,1H),5.06(d,J=7.9Hz,1H),1.15(d,J=7.4Hz,3H).; ESI-MS m / z:462[M+H]+.
[0277] Example 11 Synthesis of Compound 349 and Compound 350
[0278] Compound 82 (300 mg, 0.65 mmol) was subjected to SFC chiral separation to obtain compound 349 (112 mg, yield: 37.3%) and compound 350 (117 mg, yield: 39%).
[0279] Compound 349: 1 H NMR (400MHz, DMSO-d6) δ8.75(dd,J=2.2,1.0Hz,1H),8.09–8.04(m,2H),7.98(dd,J=8.3,1.0Hz,1H),7.93(dd,J=8.2,2.3Hz,1H),7.64(dd,J=8.8, 5.0Hz,2H),7.57(s,1H),7.50–7.41(m,3H),7.31(t,J=8.8Hz,2H),7.24( s,1H),5.06(d,J=7.9Hz,1H),1.15(d,J=7.4Hz,3H).;MS(ESI):462[M+H] + .
[0280] Analytical SFC retention time: 1.513min (Instrument: Waters UPCC with PDA Detector; Column: DAICEL CHIRALCEL OD 50x4.6mm ID, 3um; Mobile phase: A: CO2, B: isopropanol (0.05% DEA); Isocratic: 40% B; Flow rate: 4mL / min; Column temp.: 35°C).
[0281] Compound 350: 1 H NMR (400MHz, DMSO-d6) δ8.75(dd,J=2.2,1.0Hz,1H),8.09–8.04(m,2H),7.98(dd,J=8.3,1.0Hz,1H),7.93(dd,J=8.2,2.3Hz,1H),7.64(dd,J=8.8, 5.0Hz,2H),7.57(s,1H),7.50–7.41(m,3H),7.31(t,J=8.8Hz,2H),7.24( s,1H),5.06(d,J=7.9Hz,1H),1.15(d,J=7.4Hz,3H).;MS(ESI):462[M+H] + .
[0282] Analytical SFC retention time: 0.862min (Instrument: Waters UPCC with PDA Detector; Column: DAICEL CHIRALCEL OD 50x4.6mm ID, 3um; Mobile phase: A: CO2, B: isopropanol (0.05% DEA); Isocratic: 40% B; Flow rate: 4mL / min; Column temp.: 35°C).
[0283] Using the above synthesis method and different raw materials, the target compounds 1-15, 19-45, 47, 49-59, 63-71, 75-81, 83-101, 104-348 and 351-365 in Table 1 can be obtained.
[0284] Table 1
[0285] Table 2. NMR data of some compounds in Table 1
[0286] Biological Example 1 DGKζ kinase inhibitory activity assay
[0287] We used ADP-Glo in the presence or absence of compounds TM Kinase Assay (Progema) was used to detect the inhibitory effect of the test compounds on human recombinant DGKζ.
[0288] To a 384-well plate, add 3uL of DGKζ enzyme (90ng / mL) dissolved in assay buffer (40mM Tris-HCl, 10mM MgCl2, 0.1mg / mL BSA, 50μM DTT). Similarly, add 3uL of the test compound diluted in assay buffer to the target final concentration. After incubation at room temperature for 15 minutes, add 3uL of substrate (150uM 1-oleoyl-2-acetyl-sn-glycerol, 480uM phosphatidylserine, 150uM UltraPure-ATP) dissolved in lipid dilution buffer (40mM Tris-HCl, 10mM MgCl2, 0.1mg / ml BSA, 50μM DTT) and allow to react at room temperature for 30 minutes. Then, add 3uL of ADP-Glo reagent and allow to stand at room temperature for 40 minutes to terminate the enzyme reaction. Then, 6 μL of kinase detection reagent was added and the cells were allowed to stand at room temperature for 30 minutes. Luminescence was then measured using ARVOX3. The signal value in solvent treatment was set to 0% inhibition, and the signal value in the absence of DGKζ enzyme was set to 100% inhibition. The IC was calculated using Sigmoid-Emax model nonlinear regression analysis. 50 The results are shown in Table 3 below.
[0289] Table 3. Inhibitory activity of the compounds of the present invention on DGKζ kinase (IC 50 ,nM)
[0290] +++ indicates IC 50 Less than or equal to 200nM
[0291] ++ indicates IC 50 200nM to 500nM
[0292] + indicates IC 50 Greater than 500nM
[0293] Biological Example 2 DGKι kinase inhibitory activity assay reagents
[0294] Experimental consumables
[0295] Experimental instruments
[0296] Serially dilute the compound using DMSO in a 384PP Plate. Use the Echo to transfer 0.1 μL of compound to a 384-well reaction microplate (Optiplate 384), ensuring a final DMSO concentration of 1% (in duplicate). Add 5 μL of 2X enzyme solution to each well of the 384-well reaction microplate and centrifuge at 1000 rpm for 1 minute. The well containing 1% DMSO and enzyme serves as the High Control, and the well containing 1% DMSO and buffer serves as the Low Control. Incubate at 25°C for 10 minutes. Add 5 μL of 2X ATP and DAG solution to each well and centrifuge at 1000 rpm for 1 minute. Incubate at 25°C for 60 minutes. Add 5 μL of ADP-Glo Reagent to each well and centrifuge at 1000 rpm for 1 minute. Incubate at 25°C for 40 minutes. Add 10 μL of ADP-Glo Detection to each well and centrifuge at 1000 rpm for 1 minute. Incubate at 25°C for 40 minutes. RLU (Relative Luminescence Unit) signals were read on a BMG (PHERAstar FSX) microplate reader (final working concentrations of reagents: 5 nM DGKi, 20 μM ATP, 50 μM DAG). Percent inhibition of compound-treated wells was normalized between the High Control and Low Control (% inhibition = (RLU High Control - RLU compound readout) ( / RLU High Control - RLU Low Control) * 100). Results are shown in Table 4 below.
[0297] Table 4. Inhibitory activity of the compounds of the present invention on DGKι kinase (IC 50 ,nM) +++ indicates IC 50 Less than or equal to 200nM++ indicates IC 50 200nM to 500nM + indicates IC 50 Greater than 500nM
[0298] Biological Example 3 The compounds of the present invention induce IL-2 secretion in Jurkat-ADCC cells in vitro
[0299] 1. The experimental cells are shown in Table 5:
[0300] Table 5 Experimental materials
[0301] 2. Experimental instruments, reagents and consumables are shown in Tables 6, 7 and 8:
[0302] Table 6 Experimental instruments
[0303] Table 7 Experimental reagents
[0304] Table 8 Experimental consumables
[0305] 1. Experimental steps:
[0306] Day 1: Jurkat ADCC cells were seeded in 96-well plates at 1×10 5 cells / well, duplicate plates.
[0307] Day 2: The Cbl-b inhibitor (compound 21 in PCT / CN2024 / 087003, structural formula: ) at a maximum concentration of 500 nM, diluted 5-fold, and added to the cell plate in a volume of 15 μL; for combined use, the compound of this patent was diluted 5-fold at a maximum concentration of 500 nM, added to the cell plate in a volume of 15 μL, and the Cbl-b inhibitor was added to the cell plate at a constant concentration of 30 nM in a volume of 15 μL. Centrifuge at 1000 rpm for 10 seconds at room temperature, then place the cells in a 37°C incubator and culture for 2 hours. Add 3.7 μL of Immunoculture TM Human CD3 / CD28 T cell Activator was added, and the cells were centrifuged at 1000 rpm for 10 seconds at room temperature. Finally, the cells were cultured in a 37°C incubator.
[0308] Day 5: Remove the cell culture plate from the incubator and observe the cell status under a microscope. If the cells are in good condition, centrifuge at 1000 rpm for 3 minutes. Gently remove 60 μL of supernatant from the cell plate, transfer it to a 96-well flat-bottom plate, seal it with sealing film, and freeze it in a -80°C refrigerator.
[0309] 2.HTRF detection:
[0310] a) Dilute Diluent*#5 in HUMAN IL2 KITS 5-fold with distilled water. (Operate on ice)
[0311] b) Take 15 μL of the IL2 standard solution and add it to 30 μL of diluent. Mix gently. This will generate Standard 7 (8000 pg / mL). Using Standard 7, dilute Standard 6, Standard 5, Standard 4, Standard 3, Standard 2, and Standard 1 according to the table. Use this serial dilution to create a standard curve. (Work on ice)
[0312] c) Dispense 16 μL of each IL2 standard (Standard 0-Standard 7) into each standard well, and dispense 16 μL of each cell supernatant obtained in step 3 into the remaining sample wells.
[0313] d) Dispense 4 μL of pre-mixed IL2 antibody into all wells (mix the IL2 Eu Cryptate antibody and IL2-d2 antibody in the HUMAN IL2 KITS at a 1:1 ratio, then add equal volumes of Detection Buffer*#3 and water in the HUMAN IL2 KITS). (Operate on ice)
[0314] e) Seal the plate and incubate at room temperature. The signal remains stable for 24 hours.
[0315] f) Remove the plate sealer and place it in a compatible LANCE was read on a machine (PerkinElmer EnVision).
[0316] The results are shown in Tables 9 and 10 below.
[0317] Table 9. Activity of the compounds of the present invention in inducing IL2 secretion in the presence of Cbl-b inhibitors (EC 50 ,nM) +++ means EC 50 Less than or equal to 10 nM ++ indicates EC 50 10nM to 50nM + indicates EC 50 Greater than 50nM
[0318] Table 10. Activity of the compounds of the present invention in inducing IL2 secretion in the absence of Cbl-b inhibitors (EC 50 ,nM)
[0319] Biological Example 4 In vivo pharmacokinetic study of the compounds of the present invention
[0320] Female CD-1 mice aged 7 to 10 weeks were selected and administered intravenously and orally at doses of 1 mg / kg and 10 mg / kg, respectively. Mice were fasted for at least 12 hours before administration and resumed feeding 4 hours after administration. Water was freely available throughout the experiment. On the day of the experiment, animals in the intravenous group received a single injection of the corresponding compound via the tail vein at a volume of 10 mL / kg. Animals in the oral group received a single injection of the corresponding compound via gavage at a volume of 10 mL / kg. Animals were weighed before administration, and the administration volume was calculated based on body weight. Samples were collected at 0.083 (injection group), 0.167, 0.5, 1, 2, 4, 8, and 24 hours. Approximately 200 μL of whole blood was collected from the submandibular venous plexus at each time point to prepare plasma for concentration determination by high-performance liquid chromatography-tandem mass spectrometry (LC-MS / MS). All animals were euthanized by CO2 anesthesia after the collection of the PK sample at the last time point. Phoenix WinNonlin was used. TM Plasma concentrations were processed using a non-compartmental model using the pharmacokinetic software version 8.3 (Certara), and pharmacokinetic parameters were calculated using the linear-log trapezoidal method. The in vivo pharmacokinetic results are shown in Table 11 below.
[0321] Table 11 In vivo pharmacokinetic evaluation results of the compounds of the present invention
[0322] The reference compound BAY2965501 is compound 62.2 in WO2021214019A1.
[0323] As can be seen from the data in Table 6, in the mouse pharmacokinetic experiment, compared with BAY2965501, the half-life T of compound 73 and compound 349 in the present invention is 1 / 2 The longer Vdss indicates that compounds 73 and 349 have better in vivo metabolic stability. Furthermore, compared to BAY2965501, BAY29655019 exhibits a significantly higher Vdss, indicating that compounds 73 and 349 distribute less in plasma and more in other tissues, potentially offering a greater advantage in treating solid tumors. Therefore, compared to BAY2965501, compounds 73 and 349 exhibit unexpectedly improved pharmacokinetic properties.
[0324] Biological Example 5 In vitro test on the killing activity of the compounds of the present invention in promoting NK cells against tumor cells OVCAR3
[0325] Approximately 8,000 OVCAR3 cells / well and approximately 80,000 NK92MI cells / well were seeded into 96-well black clear cell culture plates, with 90 μL per well. The cells were incubated overnight at 37°C for 24 hours. The test compound was diluted to a 10-fold final concentration and 10 μL was added to the cell culture plate. The cells were incubated at 37°C for 48 hours. The OVCAR3 cell culture medium was discarded, and the OVCAR3 cells were stained with 1 μM calcein AM for 50 minutes. The cells were washed once with PBS, and 100 μL of culture medium was added. The NK92MI cells were mixed and then gently added to the OVCAR3 cells. After approximately 4 hours of co-incubation, the DMSO control group and the high-concentration drug group were photographed using PICO to observe the cytotoxicity of the NK92MI cells against the OVCAR3 cells. Co-incubation was terminated when a significant difference in cytotoxicity between the two groups was observed. The culture medium was discarded, and the cells were rinsed once with 100 μL of PBS. Add 100 μL of 4% PFA to each well and fix the cells at room temperature for 20 minutes. Rinse once with PBS and detect the fluorescence signal of the sample through the FITC channel of the microplate reader. Compare with the DMSO group and calculate the inhibition rate and IC 50 .
[0326] Biological Example 6 In Vivo Efficacy Study - Mouse MC38 Subcutaneous Transplant Tumor Model
[0327] Each C57BL / 6 mouse was subcutaneously inoculated with 1×10 6 MC38 cells, wait until the tumor grows to 100-200 mm 3 Tumor volumes were measured twice weekly and at the endpoint of dosing for the following treatments: vehicle, compound alone (oral administration, once daily), anti-PD-1 antibody alone (intravenous injection, once weekly), anti-VEGF antibody alone (intraperitoneal injection, once weekly), combination of anti-PD-1 antibody (intravenous injection, once weekly) and anti-VEGF antibody (intraperitoneal injection, once weekly), compound (oral administration, once daily) in combination with anti-PD-1 antibody (intravenous injection, once weekly), compound (oral administration, once daily) in combination with anti-VEGF antibody (intraperitoneal injection, once weekly), or compound (oral administration, once daily) in combination with anti-PD-1 antibody (intravenous injection, once weekly) and anti-VEGF antibody (intraperitoneal injection, once weekly). Tumor growth inhibition rate (TGI) of the compound was calculated as 1-(tumor volume of the dosing group on day 20 - tumor volume of the dosing group on day 1) / (tumor volume of the vehicle control group on day 20 - tumor volume of the vehicle control group on day 1).
[0328] Biological Example 7 In vivo efficacy study - mouse MC38 subcutaneous transplant tumor model
[0329] Each C57BL / 6 mouse was subcutaneously inoculated with 1×10 6 MC38 cells, wait until the tumor grows to 50-80 mm 3 Tumor volumes were measured twice weekly and at the endpoint of dosing for the following treatments: vehicle, compound alone (oral administration, once daily), anti-PD-1 antibody alone (intravenous injection, once weekly), anti-VEGF antibody alone (intraperitoneal injection, once weekly), combination of anti-PD-1 antibody (intravenous injection, once weekly) and anti-VEGF antibody (intraperitoneal injection, once weekly), compound (oral administration, once daily) in combination with anti-PD-1 antibody (intravenous injection, once weekly), compound (oral administration, once daily) in combination with anti-VEGF antibody (intraperitoneal injection, once weekly), or compound (oral administration, once daily) in combination with anti-PD-1 antibody (intravenous injection, once weekly) and anti-VEGF antibody (intraperitoneal injection, once weekly). Tumor growth inhibition rate (TGI) of the compound was calculated as 1-(tumor volume of the dosing group on day 20 - tumor volume of the dosing group on day 1) / (tumor volume of the vehicle control group on day 20 - tumor volume of the vehicle control group on day 1).
[0330] Biological Example 8 In Vivo Efficacy Study - Mouse MC38 Subcutaneous Transplant Tumor Model
[0331] Each C57BL / 6 mouse was subcutaneously inoculated with 1×10 6MC38 cells were inoculated and immediately dosed with either vehicle, compound alone (oral, once daily), anti-PD-1 antibody alone (intravenous, once weekly), anti-VEGF antibody alone (intraperitoneal, once weekly), anti-PD-1 antibody (intravenous, once weekly) in combination with anti-VEGF antibody (intraperitoneal, once weekly), compound (oral, once daily) in combination with anti-PD-1 antibody (intravenous, once weekly), compound (oral, once daily) in combination with anti-VEGF antibody (intraperitoneal, once weekly), or compound (oral, once daily) in combination with anti-PD-1 antibody (intravenous, once weekly) and anti-VEGF antibody (intraperitoneal, once weekly). Tumor volume was measured twice weekly at the endpoint. Tumor growth inhibition (TGI) was calculated as 1 - (tumor volume of the treatment group on day 20 - tumor volume of the treatment group on day 1) / (tumor volume of the vehicle control group on day 20 - tumor volume of the vehicle control group on day 1).
[0332] Biological Example 9 In Vivo Efficacy Study - Mouse CT26 Subcutaneous Transplant Tumor Model
[0333] Each BALB / c mouse was subcutaneously inoculated with 2×10 5 CT26 cells, wait until the tumor grows to 100-200 mm 3Tumor volumes were measured twice weekly and at the endpoint of dosing for the following treatments: vehicle, compound alone (oral administration, once daily), anti-PD-1 antibody alone (intravenous injection, once weekly), anti-VEGF antibody alone (intraperitoneal injection, once weekly), combination of anti-PD-1 antibody (intravenous injection, once weekly) and anti-VEGF antibody (intraperitoneal injection, once weekly), compound (oral administration, once daily) in combination with anti-PD-1 antibody (intravenous injection, once weekly), compound (oral administration, once daily) in combination with anti-VEGF antibody (intraperitoneal injection, once weekly), or compound (oral administration, once daily) in combination with anti-PD-1 antibody (intravenous injection, once weekly) and anti-VEGF antibody (intraperitoneal injection, once weekly). Tumor growth inhibition rate (TGI) of the compound was calculated as 1-(tumor volume of the dosing group on day 20 - tumor volume of the dosing group on day 1) / (tumor volume of the vehicle control group on day 20 - tumor volume of the vehicle control group on day 1).
[0334] Biological Example 10 In vivo efficacy study - mouse CT26 subcutaneous transplant tumor model
[0335] Each BALB / c mouse was subcutaneously inoculated with 2×10 5 CT26 cells, wait until the tumor grows to 50-80 mm 3 Tumor volumes were measured twice weekly and at the endpoint of dosing for the following treatments: vehicle, compound alone (oral administration, once daily), anti-PD-1 antibody alone (intravenous injection, once weekly), anti-VEGF antibody alone (intraperitoneal injection, once weekly), combination of anti-PD-1 antibody (intravenous injection, once weekly) and anti-VEGF antibody (intraperitoneal injection, once weekly), compound (oral administration, once daily) in combination with anti-PD-1 antibody (intravenous injection, once weekly), compound (oral administration, once daily) in combination with anti-VEGF antibody (intraperitoneal injection, once weekly), or compound (oral administration, once daily) in combination with anti-PD-1 antibody (intravenous injection, once weekly) and anti-VEGF antibody (intraperitoneal injection, once weekly). Tumor growth inhibition rate (TGI) of the compound was calculated as 1-(tumor volume of the dosing group on day 20 - tumor volume of the dosing group on day 1) / (tumor volume of the vehicle control group on day 20 - tumor volume of the vehicle control group on day 1).
[0336] Biological Example 11 In vivo efficacy study - mouse CT26 subcutaneous transplant tumor model
[0337] Each BALB / c mouse was subcutaneously inoculated with 2×10 5 CT26 cells were inoculated and immediately dosed with either vehicle, compound alone (oral, once daily), anti-PD-1 antibody alone (intravenous, once weekly), anti-VEGF antibody alone (intraperitoneal, once weekly), anti-PD-1 antibody (intravenous, once weekly) in combination with anti-VEGF antibody (intraperitoneal, once weekly), compound (oral, once daily) in combination with anti-PD-1 antibody (intravenous, once weekly), compound (oral, once daily) in combination with anti-VEGF antibody (intraperitoneal, once weekly), or compound (oral, once daily) in combination with anti-PD-1 antibody (intravenous, once weekly) and anti-VEGF antibody (intraperitoneal, once weekly). Tumor volume was measured twice weekly at the endpoint. Tumor growth inhibition (TGI) was calculated as 1 - (tumor volume of the treatment group on day 20 - tumor volume of the treatment group on day 1) / (tumor volume of the vehicle control group on day 20 - tumor volume of the vehicle control group on day 1).
[0338] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. A compound represented by the general formula (1) or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates: In the general formula (1): R 2 for R 3 is -CH3 or -NH2; R x For H or F: (1) When R x When H, R 4 is a 6-membered heteroaryl group, wherein the 6-membered heteroaryl group can be optionally substituted by 1 of the following groups: phenyl, wherein the phenyl group can be optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, -(C1-C3) alkylene-phenyl, -(C1-C3) alkylene-(5-6-membered) heteroaryl, -(C1-C3) alkylene-(C3-C7) heterocycloalkyl, -(C1-C3) alkylene-(OR 9 )、(C3-C7)cycloalkyl、-OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-(N(R 10 )(R 11 ))、-C(=O)-N(R 12 )(R 13 )、-S(=O) n -R 14 、-C(=O)R 14 or -C(=O)-OR 17 ; and R 1 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -OH, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, -(C1-C3) alkylene-phenyl, (C1-C6) alkoxy, -(C1-C3) alkyleneoxy-phenyl, (C1-C6) haloalkoxy or -N(R 5 )(R 6), wherein the phenyl group in the -(C1-C3)alkylene-phenyl group and the -(C1-C3)alkyleneoxy-phenyl group may each independently be optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; (2) When R x When H, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -N=S(R a )(R b )(=O)、-P(O)(R a )(R b ), (C2-C6)alkenyl, (C5-C6)cycloalkenyl, (C2-C6)alkynyl, (C2-C6)haloalkenyl, (C5-C6)halocycloalkenyl, (C2-C6)haloalkynyl, (4-7 membered)heterocycloalkyl attached via a carbon atom in the heterocycle, -O-(C2-C6)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C6)alkynyl, -O-(C1-C6)alkylene-(C3-C7)cycloalkyl, -S-(C1-C6)alkylene-(C3-C7)cycloalkyl, -O-(C1-C6)alkylene-(3-C7 membered)heterocycloalkyl, -S-(C1-C6)alkylene-(3-7)heterocycloalkyl, or -O-(C1-C6)alkylene-N(R 10 )(R 11 ), wherein the (4-7 membered) heterocycloalkyl, -O-(C1-C4) alkylene-(3-7 membered) heterocycloalkyl and the (3-7 membered) heterocycloalkyl in -S-(C1-C4) alkylene-(3-7 membered) heterocycloalkyl can each be independently optionally substituted by 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3) 2 or -CF3; and wherein the (C2-C6)alkenyl, (C5-C6)cycloalkenyl, (C2-C6)alkynyl, (C2-C6)haloalkenyl, (C5-C6)halocycloalkenyl or (C2-C6)haloalkynyl may each independently be optionally substituted by 1 or 2 of the following groups: -H, halogen, -CN, -OH, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C3-C6)alkyl, (C5-C6)alkyl ... C6) cycloalkyl, (3-7 membered) heterocycloalkyl, optionally substituted (5-7 membered) heteroaryl or optionally substituted phenyl; and R 1is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -OH, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, -(C1-C3) alkylene-phenyl, (C1-C6) alkoxy, -(C1-C3) alkyleneoxy-phenyl, (C1-C6) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl group in the -(C1-C3)alkylene-phenyl group and the -(C1-C3)alkyleneoxy-phenyl group may each independently be optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; (3) When R x When H, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, -(C1-C3) alkylene-phenyl, -(C1-C3) alkylene-(5-6 membered) heteroaryl, -(C1-C3) alkyl-(3-7 membered) heterocycloalkyl, -(C1-C6) alkylene-(OR 9 )、(C3-C7)cycloalkyl、-OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-(N(R 10 )(R 11 ))、-C(=O)-N(R 12 )(R 13 )、-S(=O) n -R 14 、-C(=O)R 14 、-C(=O)-OR 17 , (5-6 membered) heteroaryl substituted by 1 or 2 halogens or -CH3 or phenyl substituted by 1 or 2 halogens or -CH3; and R 1 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl, (C5-C6) halocycloalkenyl or (C2-C6) haloalkynyl; (4) When Rx When F, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, (C2-C6) haloalkenyl, (C5-C6) halocycloalkenyl, (C2-C6) haloalkynyl, (4-7 membered) heterocyclic alkyl, -O-(C2-C6)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C6)alkynyl, -O-(C2-C6)haloalkenyl, -O-(C5-C6)halocycloalkenyl, -O-(C2-C6)haloalkynyl, -(C1-C3)alkylene-phenyl, -(C1-C3)alkylene-(5-6 membered)heteroaryl, -(C1-C3)alkylene-(C3-C7)cycloalkyl, -(C1-C6)alkylene-(OR 9 )、(C3-C7)cycloalkyl、-OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-(N(R 10 )(R 11 ))、-C(=O)-N(R 12 )(R 13 )、-S(=O) n -R 14 、-C(=O)R 14 、-C(=O)-OR 17 , (5-6 membered) heteroaryl substituted by 1 or 2 halogens or -CH3, or phenyl substituted by 1 or 2 halogens or -CH3, wherein the (4-7 membered) heterocycloalkyl may be optionally substituted by 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2, or -CF3; and R 1 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -OH, -CN, -NO2, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, -(C1-C3) alkylene-phenyl, (C1-C6) alkoxy, -(C1-C3) alkoxy-phenyl, (C1-C6) haloalkoxy or -N(R 5 )(R 6), wherein the phenyl group in the -(C1-C3)alkylene-phenyl group and the -(C1-C3)alkyleneoxy-phenyl group may each independently be optionally substituted with 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; R a and R b Each is independently (C1-C4)alkyl or (C3-C4)cycloalkyl; R 5 and R 6 Each is independently -H, (C1-C4)alkyl, -C(=O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or -(C1-C3)alkylene-phenyl; or R 5 and R 6 The N atom to which it is attached can form a (4-7 membered) heterocycloalkyl, wherein the (4-7 membered) heterocycloalkyl can be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -OH, (C1-C4)alkyl, -C(═O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or (C1-C4)alkoxy; R 7 is H, -CH3 or -CH2CH3; R 8 is -C(=O)NH2 or -S(=O)2NH2; R 9 is H, (C1-C6) alkyl, (C2-C6) alkenyl, (C5-C6) cycloalkenyl, (C2-C6) alkynyl, (C1-C6) alkyl, -(C1-C3) alkylene-(5-6 membered) heteroaryl, -(C1-C3) alkylene-phenyl, (C1-C6) haloalkyl, hydroxy-substituted (C2-C4) alkyl, -(C2-C3) alkylene-(C1-C3) alkoxy, -(C2-C3) alkylene-OC(=O)-(C1-C3) alkyl, -C(R 18 )(R 19 )-C(=O)-OR 17 ,-C(R 18 )(R 19 )-C(=O)-N(R 20 )(R 21 )、-C(=O)-N(R 20 )(R 21), phenyl, (5-6-membered) heteroaryl or (5-6-membered) heterocycloalkyl, wherein the phenyl in -(C1-C3)alkylene-phenyl, phenyl, (5-6-membered) heteroaryl, (5-6-membered) heteroaryl and (5-6-membered) heterocycloalkyl in -(C1-C3)alkylene-(5-6-membered) heteroaryl can each be independently optionally substituted by 1 or 2 of the following groups: -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; R 10 and R 11 Each is independently -H, (C1-C4) alkyl, (C1-C4) haloalkyl, hydroxy-substituted (C2-C4) alkyl, -(C2-C3) alkylene-(C1-C3) alkoxy, -(C2-C3) alkylene-(N(R 22 )(R 23 )), -(C1-C6)alkylene-(C3-C7)cycloalkyl, -C(═O)-(C1-C4)alkyl, (C3-C7)cycloalkyl, -C(═O)-(C3-C7)cycloalkyl, -(C1-C3)alkylene-phenyl, -C(═O)-(C1-C3)alkylene-phenyl, -C(═O)-O-(C1-C3)alkylene-phenyl, phenyl or (5-6 membered)heteroaryl, wherein the (C3-C7)cycloalkyl, -(C1-C6)alkylene-(C3-C7)cycloalkyl and -C The (C3-C7)cycloalkyl, -(C1-C3)alkylene-phenyl, -C(=O)-(C1-C3)alkylene-phenyl, -C(=O)-O-(C1-C3)alkylene-phenyl, phenyl or (5-6-membered)heteroaryl in the (=O)-(C3-C7)cycloalkyl group may each be independently optionally substituted by 1 or 2 of the following groups: -H, -F, -CN, -CH3, -CH2CH3, -CF3, -OCF3, -CH2CF3, -OCH3, -OCH2CH3 or -N(CH3)2; or R 10 and R 11 The N atom to which it is attached can form a (4-11 membered) heterocycloalkyl, wherein the (4-11 membered) heterocycloalkyl can be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -OH, (C1-C4) alkyl, (C1-C4) haloalkyl, -C(=O)-(C1-C4) alkyl, (C3-C7) cycloalkyl, (C1-C4) alkoxy, -N(R 22 )(R 23 ) or (4-7 membered) heterocycloalkyl; R 12 and R 13Each is independently -H, (C1-C4) alkyl, (C1-C4) haloalkyl, hydroxy-substituted (C1-C4) alkyl, -(C2-C3) alkylene-(C1-C4) alkoxy, -(C2-C3) alkylene-(C1-C4) haloalkoxy, -(C2-C3) alkylene-phenoxy, (C3-C7) cycloalkyl, (C4-C7) heterocycloalkyl or -(C1-C3) alkylene-phenyl, wherein the phenyl, (C3-C7) cycloalkyl and (C4-C7) heterocycloalkyl in the -(C2-C3) alkylene-phenoxy and -(C1-C3) alkylene-phenyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, -N(CH3)2, (C1-C4)alkyl, (C1-C4)haloalkyl, -C(=O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or (C1-C4)alkoxy; or R 12 and R 13 The N atom to which it is connected may form a (4-7 membered) heterocycloalkyl, wherein the (4-7 membered) heterocycloalkyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, (C1-C4)alkyl, -C(═O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or (C1-C4)alkoxy; R 14 is (C1-C4) alkyl, (C1-C4) alkoxy or phenyl, wherein the phenyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; R 17 is (C1-C4)alkyl; R 18 and R 19 Each is independently -H or (C1-C4) alkyl; R 20 is H, (C1-C6) alkyl, (C3-C4) alkenyl, (C2-C4) alkynyl or (C1-C3) alkoxy, wherein the (C1-C6) alkyl may be substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, (C1-C4) alkoxy, -N(R 22 )(R 23), (C3-C11)cycloalkyl, (4-11 membered)heterocycloalkyl, phenyl or (5-10 membered)heteroaryl, wherein the phenyl or (5-10 membered)heteroaryl may be substituted by 1, 2 or 3 of the following groups: -H, -F, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; or R 20 is (C3-C11)cycloalkyl, (4-11 membered)heterocycloalkyl, wherein the (C3-C11)cycloalkyl and (4-11 membered)heterocycloalkyl may be independently substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, (C1-C4)alkyl, -C(═O)-(C1-C4)alkyl, (C3-C4)cycloalkyl or (C1-C4)alkoxy; or R 20 is phenyl, naphthyl or (5-10 membered) heteroaryl, wherein the phenyl, naphthyl and (5-10 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, (C1-C4) alkyl, (C1-C4) haloalkyl, (C1-C4) alkoxy, (C1-C4) haloalkoxy, -N(R 22 )(R 23 ) or -C(=O)(R 24 )(R 25 ); R 21 is H or (C1-C4) alkyl; or R 20 and R 21 The N atom to which it is connected can form a (4-7 membered) heterocycloalkyl, wherein the (4-7 membered) heterocycloalkyl can be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -OH, (C1-C4) alkyl, (C1-C4) haloalkyl, -(C1-C3) alkylene-phenyl, -C(═O)-(C1-C4) alkyl, (C3-C4) cycloalkyl, (C1-C4) alkoxy, (C1-C3) haloalkoxy, -N(R 22 )(R 23 ) or -C(=O)(R 24 )(R 25 ); R 22 and R 23 Each is independently -H, (C1-C2)alkyl or -C(=O)-(C1-C2)alkyl; R 24 and R 25are each independently -H or (C1-C4)alkyl; and n is an integer of 0, 1 or 2.
2. The compound according to claim 1 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 2 for 3. The compound according to claim 1 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), when R x When F, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -I, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, (C2-C4) haloalkenyl, (C5-C6) halocycloalkenyl, (C2-C4) haloalkynyl, (4 -7-membered) heterocycloalkyl, -O-(C2-C4)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C4)alkynyl, -O-(C2-C4)haloalkenyl, -O-(C5-C6)halocycloalkenyl, -O-(C2-C4)haloalkynyl, -(C1-C2)alkylene-phenyl, -(C1-C2)alkylene-(5-6-membered)heteroaryl, -(C1-C2)alkylene-(C3-C7)cycloalkyl, -(C1-C4)alkylene-(OR 9 )、(C3-C7)cycloalkyl, -OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-N(R 10 )(R 11 )、-C(=O)-N(R 12 )(R 13 ),-SR 14 、-S(=O)-R 14 、-S(=O)2-R 14 、-C(=O)R 14 、-C(=O)-OR 17, (5-6 membered) heteroaryl substituted with 1 or 2 -F, -Cl, -Br or -CH3, or phenyl substituted with 1 or 2 -F, -Cl, -Br or -CH3, wherein the (4-7 membered) heterocycloalkyl may be optionally substituted with 1 or 2 of -H, halogen, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; and R 1 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -OH, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, -(C1-C2) alkylene-phenyl, (C1-C4) alkoxy, -(C1-C2) alkyleneoxy-phenyl, (C1-C4) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl groups in the -(C1-C2)alkylene-phenyl and -(C1-C2)alkyleneoxy-phenyl groups may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -Br, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
4. The compound according to claim 3 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 is phenyl or (5-6 membered) heteroaryl containing 1, 2 or 3 independently selected from N, O or S, wherein the phenyl and (5-6 membered) heteroaryl are each independently optionally substituted by 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3; and R 1 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3.
5. The compound according to claim 4 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), when R x When F, R 4 for: R 1 for 6. The compound according to claim 1 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), when R x When H, R 4 is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -N=S(CH3)2(=O), -P(O)(CH3)2, (C2-C4)alkenyl, (C5-C6)cycloalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkenyl, (C5-C6)halocycloalkenyl, (C2-C4)haloalkynyl, (4-7 membered) heterocyclic ring connected via a carbon atom in the heterocyclic ring )heterocycloalkyl, -O-(C2-C4)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C4)alkynyl, -O-(C1-C4)alkylene-(C3-C7)cycloalkyl, -S-(C1-C4)alkylene-(C3-C7)cycloalkyl, -O-(C1-C4)alkylene-(3-7 membered)heterocycloalkyl, -S-(C1-C4)alkylene-(3-7 membered)heterocycloalkyl or -O-(C1-C4)alkylene-N(R 10 )(R 11 ), wherein the (4-7 membered) heterocycloalkyl, -O-(C1-C4) alkylene-(3-7 membered) heterocycloalkyl and the (3-7 membered) heterocycloalkyl in -S-(C1-C4) alkylene-(3-7 membered) heterocycloalkyl can each be independently optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -Br, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N( CH3)2 or -CF3; and wherein the (C2-C4)alkenyl, (C5-C6)cycloalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkenyl, (C5-C6)halocycloalkenyl or (C2-C4)haloalkynyl may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -CN, -OH, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -CF3, optionally substituted (5-6 membered) heteroaryl or optionally substituted phenyl; and R 1is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -OH, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, -(C1-C2) alkylene-phenyl, (C1-C4) alkoxy, -(C1-C2) alkyleneoxy-phenyl, (C1-C4) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl groups in the -(C1-C2)alkylene-phenyl and -(C1-C2)alkyleneoxy-phenyl groups may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -Br, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
7. The compound according to claim 6 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 is phenyl or a (5-6 membered) heteroaryl group containing 1, 2 or 3 independently selected from N, O or S, wherein the phenyl group and the (5-6 membered) heteroaryl group are each independently optionally substituted by 1, 2 or 3 of the following groups: -N=S(CH3)2(=O), -P(O)(CH3)2, (C2-C3)alkenyl, (C2-C3)haloalkenyl, (C5-C6)cycloalkenyl, (C5-C6)halocycloalkenyl, (C2-C3)alkynyl, (C2-C3)haloalkynyl, 1 or 2 groups connected via a carbon atom in the heterocyclic ring; independently selected from N, S or O (4-7 membered) heterocycloalkyl, -O-(C2-C4) alkenyl, -O-(C5-C6) cycloalkenyl, -O-(C2-C4) alkynyl, -O-(C1-C2) alkylene-(C3-C6) cycloalkyl, -S-(C1-C2) alkylene-(C3-C6) cycloalkyl, -O-(C1-C2) alkylene-(3-6 membered) heterocycloalkyl, -S-(C1-C2) alkylene-(3-6 membered) heterocycloalkyl or -O-(C1-C2) alkylene-N(R 10 )(R 11), wherein the heterocycloalkyl in said (4-7 membered) heterocycloalkyl, -O-(C1-C2) alkylene-(3-6 membered) heterocycloalkyl and -S-(C1-C2) alkylene-(3-6 membered) heterocycloalkyl can each be independently optionally substituted with 1 or 2 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3; and wherein said (C2-C3) alkenyl, (C5-C6) cycloalkenyl, (C2-C3) alkynyl, (C2-C3) haloalkenyl, (C5-C6) halocycloalkenyl or (C2-C3) haloalkynyl can each be independently optionally substituted with 1 or 2 of the following groups: -H, -F, -Cl, -CN, -OH, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -CF3, R 1 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3.
8. The compound according to claim 7 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 for: R 1 for 9. The compound according to claim 7 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 for: R 1 for 10. The compound according to claim 1 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), when R x When H, R 4is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -I, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, (C2-C4) haloalkenyl, (C5-C6) halocycloalkenyl, (C2-C4) halo Alkynyl, -O-(C2-C4)alkenyl, -O-(C5-C6)cycloalkenyl, -O-(C2-C4)alkynyl, -O-(C2-C4)haloalkenyl, -O-(C5-C6)halocycloalkenyl, -O-(C2-C4)haloalkynyl, -(C1-C2)alkylene-phenyl, -(C1-C2)alkylene-(5-6-membered)heteroaryl, -(C1-C2)alkylene-(C3-C7)cycloalkyl, -(C1-C4)alkylene-(OR 9 )、(C3-C7)cycloalkyl、-OR 9 、-N(R 10 )(R 11 )、-(C1-C3)alkylene-N(R 10 )(R 11 )、-C(=O)-N(R 12 )(R 13 ),-SR 14 、-S(=O)-R 14 、-S(=O)2-R 14 、-C(=O)R 14 、-C(=O)-OR 17 , (5-6 membered) heteroaryl substituted by 1 or 2 -F, -Cl, -Br or -CH3 or phenyl substituted by 1 or 2 -F, -Cl, -Br or -CH3; and R 1 is phenyl or (5-6 membered)heteroaryl, wherein the phenyl or (5-6 membered)heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: (C2-C4)alkenyl, (C5-C6)cycloalkenyl, (C2-C4)alkynyl, (C2-C4)haloalkenyl, (C5-C6)halocycloalkenyl or (C2-C4)haloalkynyl.
11. The compound according to claim 10 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3; and R 1is phenyl, wherein the phenyl is independently optionally substituted by 1, 2 or 3 of the following groups: (C2-C3)alkenyl, (C2-C3)alkynyl, (C2-C3)haloalkenyl, (C5-C6)cycloalkenyl, (C5-C6)halocycloalkenyl.
12. The compound according to claim 11 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 for: R 1 for 13. The compound according to claim 1 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), when R x When H, R 4 is a 6-membered heteroaryl group, wherein the 6-membered heteroaryl group can be optionally substituted by 1 of the following groups: phenyl, wherein the phenyl group can be optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, -(C1-C2) alkylene-phenyl, -(C1-C2) alkylene-(5-6-membered) heteroaryl, -(C1-C2) alkylene-(C3-C7) heterocycloalkyl, -(C1-C2) alkylene-(OR 9 )、(C3-C7)cycloalkyl、-OR 9 、-N(R 10 )(R 11 )、-(C1-C2)alkylene-N(R 10 )(R 11 )、-C(=O)-N(R 12 )(R 13 ),-SR 14 、-S(=O)-R 14 、-S(=O)2-R 14 、-C(=O)R 14 or -C(=O)-OR 17 ;and R 1is phenyl or (5-6 membered) heteroaryl, wherein the phenyl or (5-6 membered) heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -OH, -CN, -NO2, (C1-C4) alkyl, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, -(C1-C2) alkylene-phenyl, (C1-C4) alkoxy, -(C1-C2) alkyleneoxy-phenyl, (C1-C4) haloalkoxy or -N(R 5 )(R 6 ), wherein the phenyl groups in the -(C1-C2)alkylene-phenyl and -(C1-C2)alkyleneoxy-phenyl groups may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -Br, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
14. The compound according to claim 13 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 is a 6-membered heteroaryl containing 1 or 2 N, wherein the 6-membered heteroaryl is substituted by 1 of the following groups: phenyl, wherein the phenyl is independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -Br, -CN, -NO2, -CH3, -CH2CH3, -CHF2, -CF3, -OR 9 、-N(R 10 )(R 11 )、-C(=O)-N(R 12 )(R 13 );and R 1 is phenyl, wherein the phenyl group is independently optionally substituted with 1, 2 or 3 of the following groups: H, F, Cl, Br, CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3.
15. The compound according to claim 14 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 for: R 1 for 16. The compound according to claim 14 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 for 17. The compound according to any one of claims 1 to 16 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R a and R b Each is independently -CH3 or -CH2CH3.
18. The compound according to any one of claims 1 to 17 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 5 and R 6 Each is independently -H, (C1-C3)alkyl, -C(=O)-(C1-C3)alkyl, (C3-C4)cycloalkyl or -(C1-C2)alkylene-phenyl; or R 5 and R 6 The N atom to which it is attached can form a (4-6 membered) heterocycloalkyl, wherein the (4-6 membered) heterocycloalkyl can be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -OH, -CH3, -CH2CH3, -C(=O)-CH3, -OCH3 or -OCH2CH3.
19. The compound according to claim 18 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 5 and R 6 are independently -H, -CH3, -CH2CH3, -C(=O)-CH3, 20. The compound according to any one of claims 1 to 19 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 9 is H, (C1-C4) alkyl, (C2-C4) alkenyl, (C5-C6) cycloalkenyl, (C2-C4) alkynyl, (C1-C4) alkyl, -(C1-C2) alkylene-(5-6 membered) heteroaryl, -(C1-C2) alkylene-phenyl, (C1-C4) haloalkyl, hydroxy-substituted (C2-C3) alkyl, -(C2-C3) alkylene-(C1-C2) alkoxy, -(C2-C3) alkylene-OC(=O)-(C1-C2) alkyl, -C(R 18 )(R 19 )-C(=O)-OR17 ,-C(R 18 )(R 19 )-C(=O)-N(R 20 )(R 21 )、-C(=O)-N(R 20 )(R 21 ), phenyl, (5-6 membered) heteroaryl or (5-6 membered) heterocycloalkyl, wherein the phenyl in the -(C1-C2)alkylene-phenyl, the phenyl, the (5-6 membered) heteroaryl, the (5-6 membered) heteroaryl and the (5-6 membered) heterocycloalkyl in the -(C1-C2)alkylene-(5-6 membered) heteroaryl may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -Cl, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
21. The compound according to claim 20 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 9 For H. -CHF2, -CF3, -CH2CF3, 22. The compound according to any one of claims 1 to 21 or any of its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 10 and R 11 Each is independently -H, (C1-C2) alkyl, (C1-C2) haloalkyl, hydroxy-substituted (C2-C3) alkyl, -(C2-C3) alkylene-(C1-C2) alkoxy, -(C2-C3) alkylene-N(R 22 )(R 23), -(C1-C2)alkylene-(C3-C7)cycloalkyl, -C(=O)-(C1-C2)alkyl, (C3-C7)cycloalkyl, -C(=O)-(C3-C7)cycloalkyl, -(C1-C2)alkylene-phenyl, -C(=O)-(C1-C2)alkylene-phenyl, -C(=O)-O-(C1-C2)alkylene-phenyl, phenyl or (5-6 membered)heteroaryl, wherein the (C3-C7)cycloalkyl, -(C1-C6)alkyl-(C3-C7)cycloalkyl and -C(=O)-(C3-C7)cycloalkyl are The (C3-C7)cycloalkyl in -(C3-C7)cycloalkyl, -(C1-C2)alkylene-phenyl and -C(═O)-(C1-C2)alkylene-phenyl and the phenyl, phenyl or (5-6-membered)heteroaryl in -C(═O)-O-(C1-C2)alkylene-phenyl may each independently be optionally substituted by 1 or 2 of the following groups: -H, -F, -CN, -CH3, -CH2CH3, -CF3, -OCF3, -CH2CF3, -OCH3, -OCH2CH3 or -N(CH3)2; or R 10 and R 11 The N atom to which it is connected may form a (4-7 membered) heterocycloalkyl, wherein the (4-7 membered) heterocycloalkyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -CN, -OH, -CH3, -CH2CH3, -CF3, CH3-C(=O)-, -OCH3, -OCH2CH3, -NH2, -N(CH3)2 or (4-7 membered)heterocycloalkyl.
23. The compound according to claim 22 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 10 and R 11 are independently -H, -CH3, -CH2CH3, -C(=O)-CH3, 24. The compound according to any one of claims 1 to 23 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 12 and R 13Each is independently -H, (C1-C3) alkyl, (C1-C3) haloalkyl, hydroxy-substituted (C1-C3) alkylene-(C1-C3) alkoxy, -(C2-C3) alkylene-(C1-C3) haloalkoxy, -(C2-C3) alkylene-phenoxy, (C3-C7) cycloalkyl, (C4-C7) heterocycloalkyl or -(C1-C2) alkylene-phenyl, wherein the phenyl, (C3-C7) cycloalkyl and (C4-C7) heterocycloalkyl in the -(C2-C3) alkylene-phenoxy and -(C1-C2) alkylene-phenyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, -N(CH3)2, -CH3, -CH2CH3, -CF3, -C(=O)-CH3, -OCH3 or -OCH2CH3; or R 12 and R 13 The N atom to which it is connected may form a (4-7 membered) heterocycloalkyl, wherein the (4-7 membered) heterocycloalkyl may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, -CH3, -CH2CH3, CH3-C(=O)-, -OCH3 or -OCH2CH3.
25. The compound according to claim 24 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 12 and R 13 are independently -H, -CH3, -CH2CH3, 26. The compound according to any one of claims 1 to 25 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R 14 is (C1-C2) alkyl, (C1-C2) alkoxy or phenyl, wherein the phenyl group may be independently optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3.
27. The compound according to claim 26 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 14is -CH3, -CH2CH3, -OCH3 or -OCH2CH3.
28. The compound according to any one of claims 1 to 27 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 17 It is -CH3 or -CH2CH3.
29. The compound according to any one of claims 1 to 28 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 18 and R 19 Each is independently -H, -CH3 or -CH2CH3.
30. The compound according to any one of claims 1 to 29 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R 20 is H, (C1-C3)alkyl, (C3-C4)alkenyl, (C2-C4)alkynyl or (C1-C3)alkoxy, wherein the (C1-C3)alkyl may be substituted by 1, 2 or 3 of the following groups: -H, -F, -Cl, -CN, -OCH3, -OCH2CH3, -NH2, -N(CH3)2, (C3-C7)cycloalkyl, (4-7 membered)heterocycloalkyl, phenyl or (5-10 membered)heteroaryl, wherein the phenyl or (5-10 membered)heteroaryl may be substituted by 1, 2 or 3 of the following groups: -H, -F, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -CF3; or R 20 is (C3-C7)cycloalkyl, (4-7 membered)heterocycloalkyl, wherein the (C3-C7)cycloalkyl and (4-7 membered)heterocycloalkyl may be independently substituted by 1, 2 or 3 of the following groups: -H, -CN, -OH, -CH3, -CH2CH3, CH3-C(=O)-, -OCH3 or -OCH2CH3; or R 20 It is phenyl, naphthyl or (5-10 membered)heteroaryl, wherein the phenyl, naphthyl and (5-10 membered)heteroaryl may each independently be optionally substituted by 1, 2 or 3 of the following groups: -H, -CN, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -CF3, -N(CH3)2 or -C(=O)(CH3)2.
31. The compound according to any one of claims 1 to 30 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R 21 is H, -CH3 or -CH2CH3; or R 20 and R 21 The N atom to which it is connected can form a (4-7 membered) heterocycloalkyl, wherein the (4-7 membered) heterocycloalkyl can be independently optionally substituted by 1, 2 or 3 of the following groups: -H, halogen, -CN, -OH, -CH3, -CH2CH3, -CF3, -(C1-C2)alkylene-phenyl, -C(=O)-CH3, -OCH3, -OCH2CH3, -OCF3, -N(CH3)2 or -C(=O)(CH3)2.
32. The compound according to any one of claims 1 to 31 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R 22 and R 23 Each is independently -H, -CH3, -CH2CH3 or -C(=O)-CH3.
33. The compound according to any one of claims 1 to 32 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R 24 and R 25 Each is independently -H, -CH3 or -CH2CH3.
34. The compound according to any one of claims 1 to 33 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), the compound has one of the following structures:
35. The compound according to any one of claims 1 to 33 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), the compound has one of the following structures:
36. The compound according to any one of claims 1 to 33 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), the compound has one of the following structures:
37. A pharmaceutical composition, characterized in that It contains a pharmaceutically acceptable excipient or carrier, and the compound according to any one of claims 1 to 36, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as active ingredients.
38. Use of a compound as described in any one of claims 1 to 36, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, or the pharmaceutical composition as described in claim 37 in the preparation of a medicament for treating or preventing a disease mediated by DGKζ.
39. The use of claim 38, wherein the disease is cancer, and the cancer is a blood cancer and a solid tumor, preferably head and neck cancer, kidney cancer, ovarian cancer, intestinal cancer, urothelial carcinoma, melanoma, liver cancer, gastric cancer, lung cancer, bladder cancer and cancer metastasis thereof.
Citation Information
Patent Citations
Substituted aminothiazoles as DGKZETA inhibitors for immune activation
CN115697979A
Substituted aminothiazoles as DGKZETA inhibitors for immune activation
CN115697980A
Novel piperidine substituted diaminothiazoles
CN1942464A
Diaminothiazole compounds, compositions and methods of use
WO2018089902A1
Aminothiazoles as inhibitors of vanin-1
WO2019133445A1
Cited By
Compound as DGKζ inhibitor
WO2025167814A1
